PROCESS FOR DESIZING CELLULOSIC FABRIC

Abstract: A process for desizing cellulose-containing fabric comprises treating the fabric with a modified enzyme (enzyme hybrid) which comprises a catalytically active amino acid sequence of an enzyme, particularly a non-cellulolytic enzyme, linked to an amino acid sequence comprising a cellulose-binding domain. A desizing composition suitable for use in the process comprises an enzyme hybrid of the type in question and a wetting agent.

Description: PROCESS FOR DESIZING CELLULOSIC FABRIC FIELD OF THE INVENTION The present invention relates to an improved enzymatic process for desizing [i.e. removing "size" ( vide infra) from] fabric or textile, more particularly cellulose-containing fabric or textile, and to a composition for use in the process. BACKGROUND OF THE INVENTION During the weaving of textiles, the threads are exposed to considerable mechanical strain. In order to prevent breaking, they are usually reinforced by coating ("sizing") with a gel¬ atinous substance ("size"). The most common sizing agent is starch in native or modified form. However, other polymeric substances, for example poly- vinylalcohol (PVA) , polyvinylpyrrolidone (PVP) , polyacrylic acid (PAA) or derivatives of cellulose [e.g. carboxy¬ methylcellulose (CMC) , hydroxyethylcellulose, hydroxypropyl¬ cellulose or methylcellulose] may also be abundant in the size. Small amounts of, e.g., fats or oils may also be added to the size as a lubricant. As a consequence of the presence of the size, the threads of the fabric are not able to absorb water, finishing agents or other compositions (e.g. bleaching, dyeing or crease-proofing compositions) to a sufficient degree. Uniform and durable finishing of the fabric can thus be achieved only after removal of the size from the fabric; a process of removing size for this purpose is known as a "desizing" process. In cases where the size comprises a starch, the desizing treatment may be carried out using a starch-degrading enzyme (e.g. an amylase) . In cases where the size comprises fat and/or oil, the desizing treatment may comprise the use of a lipolytic enzyme (a lipase) . In cases where the size comprises a significant amount of carboxymethylcellulose (CMC) or other cellulose-derivatives, the desizing treatment may be carried out with a cellulolytic enzyme, either alone or in combination with other substances, optionally in combination with other enzymes, such as amylases and/or lipases. It is an object of the present invention to achieve improved enzyme performance under desizing conditions by modifying the enzyme so as to alter (increase) the affinity of the enzyme for cellulosic fabric, whereby the modified enzyme comes into closer contact with the sizing agent in question. SUMMARY OF THE INVENTION It has now surprisingly been found possible to achieve improved enzymatic removal of a sizing agent present on cellulose-containing fabric or textile by means of an enzymatic process wherein the fabric or textile is contacted with an enzyme which has been modified so as to have increased affinity (relative to the unmodified enzyme) for binding to a cellulosic fabric or textile. DETAILED DESCRIPTION OF THE INVENTION The present invention thus relates, inter alia , to a process for desizing cellulosic fabric or textile, wherein the fabric or textile is treated (normally contacted in aqueous medium) with a modified enzyme (enzyme hybrid) which comprises a catalytically (enzymatically) active amino acid sequence of an enzyme, in particular of a non-cellulolytic enzyme, linked to an amino acid sequence comprising a cellulose-binding domain. The term "desizing" is intended to be understood in a conven¬ tional manner, i.e. the removal of a sizing agent from the fabric. The terms "cellulose-containing" and "cellulosic" when used herein in connection with fabric or textile are intended to indicate any type of fabric, in particular woven fabric, prepared from a cellulose-containing material, such as cotton, or from a cellulose-derived material (prepared, e.g., from wood pulp or from cotton) . In the present context, the term "fabric" is intended to include garments and other types of processed fabrics, and is used interchangeably with the term "textile". Examples of cellulosic fabric manufactured from naturally occurring cellulosic fibre are cotton, ramie, jute and flax (linen) fabrics. Examples of cellulosic fabrics made from man- made cellulosic fibre are viscose (rayon) and lyocell (e.g. Tencel™) fabric; also of relevance in the context of the invention are all blends of cellulosic fibres (such as vi¬ scose, lyocell, cotton, ramie, jute or flax) with other fi¬ bres, such as wool, polyester, polyacrylic, polyamide or po- lyacetate fibres. Specific examples of blended cellulosic fabric are viscose/cotton blends, lyocell/cotton blends (e.g. Tencel™/cotton blends) , viscose/wool blends, lyocell/wool blends, cotton/wool blends, cotton/polyester blends, viscose/- cotton/polyester blends, wool/cotton/polyester blends, and flax/cotton blends. Cellulose-bindinα domains Although a number of types of carbohydrate-binding domains have been described in the patent and scientific literature, the majority thereof - many of which derive from cellulolytic enzymes (cellulases) - are commonly referred to as "cellulose-binding domains"; a typical cellulose-binding domain (CBD) will thus be one which occurs in a cellulase and which binds preferentially to cellulose and/or to poly- or oligosaccharide fragments thereof . Cellulose-binding (and other carbohydrate-binding) domains are polypeptide amino acid sequences which occur as integral parts of large polypeptides or proteins consisting of two or more polypeptide amino acid sequence regions, especially in hydrolytic enzymes (hydrolases) which typically comprise a catalytic domain containing the active site for substrate hydrolysis and a carbohydrate-binding domain for binding to the carbohydrate substrate in question. Such enzymes can comprise more than one catalytic domain and one, two or three carbohydrate-binding domains, and they may further comprise one or more polypeptide amino acid sequence regions linking the carbohydrate-binding domain(s) with the catalytic domain(s) , a region of the latter type usually being denoted a "linker". Examples of hydrolytic enzymes comprising a cellulose-binding domain are cellulases, xylanases, mannanases, arabinofuranosidases, acetylesterases and chitinases. "Cellulose-binding domains" have also been found in algae, e.g. in the red alga Porphyra purpurea in the form of a non- hydrolytic polysaccharide-binding protein [see P. Tomme et al. , Cellulose-Binding Domains - Classification and Properties. in: Enzymatic Degradation of Insoluble Carbohydrates. John N. Saddler and Michael H. Penner (Eds.) , ACS Symposium Series, No. 618 (1996)] . However, most of the known CBDs [which are classified and referred to by P. Tomme et al . ( op ci t . ) as "cellulose-binding domains"] derive from cellulases and xylanases. In the present context, the term "cellulose-binding domain" is intended to be understood in the same manner as in the latter reference (P. Tomme et al. , op. ci t) . The P. Tomme et al . reference classifies more than 120 "cellulose-binding domains" into 10 families (I-X) which may have different functions or roles in connection with the mechanism of substrate binding. However, it is to be anticipated that new family representatives and additional families will appear in the future, and in connection with the present invention a representative of one such new CBD family has in fact been identified (see Example 2 herein) . In proteins/polypeptides in which CBDs occur (e.g. enzymes, typically hydrolytic enzymes such as cellulases) , a CBD may be located at the N or C terminus or at an internal position. That part of a polypeptide or protein (e.g. hydrolytic enzyme) which constitutes a CBD per se typically consists of more than about 30 and less than about 250 amino acid residues. For example: those CBDs listed and classified in Family I in accordance with P. Tomme et al. ( op . ci t . ) consist of 33-37 amino acid residues, those listed and classified in Family Ila consist of 95-108 amino acid residues, those listed and classified in Family VI consist of 85-92 amino acid residues, whilst one CBD (derived from a cellulase from Clostridium thermocell um) listed and classified in Family VII consists of 240 amino acid residues. Accordingly, the molecular weight of an amino acid sequence constituting a CBD per se will typically be in the range of from about 4kD to about 40kD, and usually below about 35kD. Enzyme hybrids Enzyme classification numbers (EC numbers) referred to in the present specification with claims are in accordance with the Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology, Academic Press Inc., 1992. A modified enzyme (enzyme hybrid) for use in accordance with the invention comprises a catalytically active (enzymatically active) amino acid sequence (in general a polypeptide amino acid sequence) of an enzyme, more particularly of a non- cellulolytic enzyme (i.e. a catalytically active amino acid sequence of an enzyme other than a cellulase) , useful in relation to desizing, in particular of an enzyme selected from the group consisting of amylases (e.g. α-amylases, EC 3.2.1.1) and lipases (e.g. triacylglycerol lipases, EC 3.1.1.3) , fused (linked) to an amino acid sequence comprising a cellulose- binding domain. The catalytically active amino acid sequence in question may comprise or consist of, for example, the whole of - or substantially the whole of - the full amino acid sequence of the mature enzyme in question, or it may consist of a portion of the full sequence which retains substantially the same catalytic (enzymatic) properties as the full sequence. Modified enzymes (enzyme hybrids) of the type in question, as well as detailed descriptions of the preparation and purification thereof, are known in the art [see, e.g., WO 90/00609, WO 94/24158 and WO 95/16782, as well as Greenwood et al., Biotechnology and Bioengineering 44 (1994) pp. 1295- 1305] . They may, e.g., be prepared by transforming into a host cell a DNA construct comprising at least a fragment of DNA encoding the cellulose-binding domain ligated, with or without a linker, to a DNA sequence encoding the enzyme of interest, and growing the transformed host cell to express the fused gene. One relevant, but non-limiting, type of recombinant product (enzyme hybrid) obtainable in this manner - often referred to in the art as a "fusion protein" - may be described by one of the following general formulae: A-CBD-MR-X-B A-X-MR-CBD-B In the latter formulae, CBD is an amino acid sequence comprising at least the cellulose-binding domain (CBD) per se. MR (the middle region; a linker) may be a bond, or a linking group comprising from 1 to about 100 amino acid residues, in particular of from 2 to 40 amino acid residues, e.g. from 2 to 15 amino acid residues. MR may, in principle, alternatively be a non-amino-acid linker. X is an amino acid sequence comprising the above-mentioned, catalytically (enzymatically) active sequence of amino acid residues of a polypeptide encoded by a DNA sequence encoding the non-cellulolytic enzyme of interest. The moieties A and B are independently optional. When present, a moiety A or B constitutes a terminal extension of a CBD or X moiety, and normally comprises one or more amino acid residues . It will thus, inter alia, be apparent from the above that a CBD in an enzyme hybrid of the type in question may be positioned C-terminally, N-terminally or internally in the enzyme hybrid. Correspondingly, an X moiety in an enzyme hybrid of the type in question may be positioned N-terminally, C-terminally or internally in the enzyme hybrid. Enzyme hybrids of interest in the context of the invention include enzyme hybrids which comprise more than one CBD, e.g. such that two or more CBDs are linked directly to each other, or are separated from one another by means of spacer or linker sequences (consisting typically of a sequence of amino acid residues of appropriate length) . Two CBDs in an enzyme hybrid of the type in question may, for example, also be separated from one another by means of an -MR-X- moiety as defined above. A very important issue in the construction of enzyme hybrids of the type in question is the stability towards proteolytic degradation. Two- and multi-domain proteins are particularly susceptible towards proteolytic cleavage of linker regions connecting the domains. Proteases causing such cleavage may, for example, be subtilisins, which are known to often exhibit broad substrate specificities [see, e.g.: Grøn et al. , Biochemistry 31 (1992), pp. 6011-6018; Teplyakov et al. , Protein Engineering 5. (1992) , pp. 413-420] . Glycosylation of linker residues in eukaryotes is one of Nature's ways of preventing proteolytic degradation. Another is to employ amino acids which are less favoured by the surrounding proteases. The length of the linker also plays a role in relation to accessibility by proteases. Which "solution" is optimal depends on the environment in which the enzyme hybrid is to function. When constructing new enzyme hybrid molecules, linker stability thus becomes an issue of great importance. The various linkers described in examples presented herein ( vide infra) in the context of the present invention are intended to take account of this issue. Cellulases (cellulase genes) useful for preparation of CBDs Techniques suitable for isolating a cellulaε-; gene are well known in the art. In the present context, the terms "cellulase" and "cellulolytic enzyme" refer to an enzyme which catalyses the degradation of cellulose to glucose, cellobiose, triose and/or other cello-oligosaccharides. Preferred cellulases (i.e. cellulases comprising preferred CBDs) in the present context are microbial cellulases, particularly bacterial or fungal cellulases. Endoglucanases, notably endo-1, 4-β-glucanases (EC 3.2.1.4), particularly monocomponent (recombinant) endo-1, 4-β-glucanases, are a preferred class of cellulases, . Useful examples of bacterial cellulases are cellulases derived from or producible by bacteria from the group consisting of Pseudomonas, Bacillus, Cellulomonas , Clostridium, Microspora, Thermotoga , Caldocellum and Actinomycets such as Streptomyces, Termomonospora and Acidothe us, in particular from the group consisting of Pseudomonas cellulolyticus , Bacillus lautus, Cellulomonas fimi , Clostridium thermocellum , Microspora bispora, Termomonospora fusca, Termomonospora cellulolyticum and Acidothemus cellulolyticus . The cellulase may be an acid, a neutral or an alkaline cellulase, i.e. exhibiting maximum cellulolytic activity in the acid, neutral or alkaline range, respectively. A useful cellulase is an acid cellulase, preferably a fungal acid cellulase, which is derived from or producible by fungi from the group of genera consisting of Trichoderma, Myrothecium, Aspergillus , Phanaerochaete, Neurospora, Neocallimastix and Botrytis . A preferred useful acid cellulase is one derived from or producible by fungi from the group of species consisting of Trichoderma viride, Trichoderma reesei , Trichoderma longibra- chiatum, Myrothecium verrucaria, Aspergillus niger, Aspergil - lus oryzae, Phanaerochaete chrysosporium, Neurospora crassa, Neocallimastix partriciarum and Botrytis cinerea . Another useful cellulase is a neutral or alkaline cellulase, preferably a fungal neutral or alkaline cellulase, which is derived from or producible by fungi from the group of genera consisting of Aspergillus, Penicilliu , Myceliophthora, Humicola, Irpex, Fusarium, Stachybotrys , Scopulariopsis, Chaetomium, Mycogone, Verticillium, Myrothecium, Papulospora, Gliocladium, Cephalosporium and Acremonium. A preferred alkaline cellulase is one derived from or produ¬ cible by fungi from the group of species consisting of Humicola insolens, Fusarium oxysporum, Myceliopthora ther- mophila, Penicillium janthinellum and Cephalosporium sp., preferably from the group of species consisting of Humicola insolens DSM 1800, Fusarium oxysporum DSM 2672, Myceliopthora thermophila CBS 117.65, and Cephalosporium sp. RYM-202. A preferred cellulase is an alkaline endoglucanase which is i munologically reactive with an antibody raised against a highly purified ~43kD endoglucanase derived from Humicola insolens DSM 1800, or which is a derivative of the latter ~43kD endoglucanase and exhibits cellulase activity. Other examples of useful cellulases are variants of parent cellulases of fungal or bacterial origin, e.g. variants of a parent cellulase derivable from a strain of a species within the fungal genera Humicola, Trichoderma , Fusarium or My eel i oph thora . Isolation of a cellulose-binding domain In order to isolate a cellulose-binding domain of, e.g., a cellulase, several genetic engineering approaches may be used. One method uses restriction enzymes to remove a portion of the gene and then to fuse the remaining gene-vector fragment in frame to obtain a mutated gene that encodes a protein truncated for a particular gene fragment. Another method involves the use of exonucleases such as Bal31 to systematically delete nucleotides either externally from the 5 ' and the 3 ' ends of the DNA or internally from a restricted gap within the gene. These gene-deletion methods result in a mutated gene encoding a shortened gene molecule whose expression product may then be evaluated for substrate-binding (e.g. cellulose-binding) ability. Appropriate substrates for evaluating the binding ability include cellulosic materials such as Avicel™ and cotton fibres . Other methods include the use of a selective or specific protease capable of cleaving a CBD, e.g. a terminal CBD, from the remainder of the polypeptide chain of the protein in question. As already indicated ( vide supra) , once a nucleotide sequence encoding the substrate-binding (carbohydrate-binding) region has been identified, either as cDNA or chromosomal DNA, it may then be manipulated in a variety of ways to fuse it to a DNA sequence encoding the enzyme or enzymatically active amino acid sequence of interest . The DNA fragment encoding the carbohydrate-binding amino acid sequence, and the DNA encoding the enzyme or enzymatically active amino acid sequence of interest are then ligated with or without a linker. The resulting ligated DNA may then be manipulated in a variety of ways to achieve expression. Preferred microbial expression hosts include certain Aspergillus species (e.g. A. niger or A. oryzae) , Bacillus species, and organisms such as Escherichia coli or Saccharomyces cerevisiae . Amylolvtic enzymes Amylases (e.g. α- or β-amylases) which are appropriate as the basis for enzyme hybrids of the types employed in the context of the present invention include those of bacterial or fungal origin. Chemically or genetically modified mutants of such amylases are included in this connection. Relevant α-amylases include, for example, α-amylases obtainable from Bacillus species, in particular a special strain of B . licheniformis, described in more detail in GB 1296839. Relevant commercially available amylases include Duramyl™, Termamyl™, Fungamyl™ and BAN™ (all available from Novo Nordisk A/S, Bagsvaerd, Denmark) , and Rapidase™ and Maxamyl™ P (available from Gist- Brocades, Holland) . Other useful amylolytic enzymes are CGTases (cyclodextrin glucanotransferases, EC 2.4.1.19), e.g. those obtainable from species of Bacillus, Thermoanaerobactor or Thermoanaero - bacterium. Lipolytic enzvmes Lipolytic enzymes (lipases) which are appropriate as the basis for enzyme hybrids of the types employed in the context of the present invention include those of bacterial or fungal origin. Chemically or genetically modified mutants of such lipases are included in this connection. Examples of useful lipases include a Humicola lanuginosa lipase, e.g. as described in EP 258 068 and EP 305 216; a Rhizomucor iehei lipase, e.g. as described in EP 238 023; a Candida lipase, such as a C. antarctica lipase, e.g. the C. antarctica lipase A or B described in EP 214 761; a Pseudomonas lipase, such as one of those described in EP 721 981 (e.g. a lipase obtainable from a Pseudomonas sp. SD705 strain having deposit accession number FERM BP-4772) , in PCT/JP96/00426, in PCT/JP96/00454 (e.g. a P. solanacearum lipase) , in EP 571 982 or in WO 95/14783 (e.g. a P. mendocina lipase) , a P. alcaligenes or P. pseudoal cal i genes lipase, e.g. as described in EP 218 272, a P. cepacia lipase, e.g. as described in EP 331 376, a P. stutzeri lipase, e.g. as disclosed in GB 1,372,034, or a P. fluorescens lipase; a Bacillus lipase, e.g. a B . subtilis lipase [Dartois et al . , Biochemica et Biophysica Acta 1131 (1993) pp. 253-260] , a B . stearothermophilus lipase (JP 64/744992) and a B . pumilus lipase (WO 91/16422) . Furthermore, a number of cloned lipases may be useful, includ¬ ing the Penicillium camembertii lipase described by Yamaguchi et al. in Gene 103 (1991) , pp. 61-67, the Geotricum candidum lipase [Y. Schimada et al., J. Biochem. 106 (1989) , pp. 383- 388] , and various Rhizopus lipases such as an R . delemar lipase [M.J. Hass et al., Gene 109 (1991) pp. 117-113] , an R . niveus lipase [Kugimiya et al. , Biosci. Biotech. Biochem. 5_6_ (1992) , pp. 716-719] and a R . oryzae lipase. Other potentially useful types of lipolytic enzymes include cutinases, e.g. a cutinase derived from Pseudomonas mendocina as described in WO 88/09367, or a cutinase derived from Fusarium solani f. pisi (described, e.g., in WO 90/09446). Suitable commercially available lipases include Lipolase™ and Lipolase Ultra™ (available from Novo Nordisk A/S) , Ml Lipase™, Lumafast™ and Lipomax™ (available from Gist-Broca- des) and Lipase P "Amano" (available from Amano Pharmaceutical Co. Ltd. ) . Plasmids Preparation of plasmids capable of expressing fusion proteins having the amino acid sequences derived from fragments of more than one polypeptide is well known in the art (see, for example, WO 90/00609 and WO 95/16782) . The expression cassette may be included within a replication system for episomal maintenance in an appropriate cellular host or may be provided without a replication system, where it may become integrated into the host genome. The DNA may be introduced into the host in accordance with known techniques such as transformation, microinjection or the like. Once the fused gene has been introduced into the appropriate host, the host may be grown to express the fused gene. Normally it is desirable additionally to add a signal sequence which provides for secretion of the fused gene. Typical examples of useful fused genes are: Signal sequence -- (pro-peptide) -- carbohydrate-binding domain -- linker -- enzyme sequence of interest, or Signal sequence -- (pro-peptide) -- enzyme sequence of interest -- linker -- carbohydrate-binding domain, in which the pro-peptide sequence normally contains 5-100, e.g. 5-25, amino acid residues. The recombinant product may be glycosylated or non- glycosylated. Determination of α-amγlolvtic activity (KNU) The α-amylolytic activity of an enzyme or enzyme hybrid may be determined using potato starch as substrate. This method is based on the break-down (hydrolysis) of modified potato starch, and the reaction is followed by mixing samples of the starch/enzyme or starch/enzyme hybrid solution with an iodine solution. Initially, a blackish-blue colour is formed, but during the break-down of the starch the blue colour becomes weaker and gradually turns to a reddish-brown. The resulting colour is compared with coloured glass calibration standards. One Kilo Novo α-Amylase Unit (KNU) is defined as the amount of enzyme (enzyme hybrid) which, under standard conditions (i.e. at 37±0.05°C, 0.0003 M Ca 2 \ pH 5.6) dextrinizes 5.26 g starch dry substance (Merck Amylum solubile) per hour. Determination of lipolytic activity (LU) The lipolytic (lipase) activity of an enzyme or enzyme hybrid may be determined using tributyrin (glyceryl tributyrate) as substrate. This method is based on the hydrolysis of tributyrin by the enzyme or enzyme hybrid, and the alkali consumption is registered as a function of time. One Lipase Unit (LU) is defined as the amount of enzyme (enzyme hybrid) which, under standard conditions (i.e. at 30.0°C, pH 7.0; with Gum Arabic as emulsifier and tributyrin 16 as substrate) liberates 1 μmol of titratable butyric acid per minute . Process conditions It will be understood that the method of the invention may be performed in accordance with any suitable desizing procedure known in the art, e.g. as described by E.S. Olson in Textile Wet Processes, Vol . I , Noyes Publication, Park Ridge, New Jersey, USA (1983) , or by M. Peter and H.K. Rouette in Grundlagen der Textilveredlung, Deutsche Fachverlag GmbH, Frankfurt am Main, Germany (1988) . Thus, the process condi¬ tions to be used in performing the present invention may be selected so as to match particular equipment or a particular type of process which it is desirable to use. Preferred examples of types of procedures suitable for use in connection with the present invention include Jigger/Winch, Pad-Roll and Pad-Steam types. These types are dealt with in further detail below. The process of the invention may be carried out as a batch, semi-continuous or continuous process. As an example, the process may comprise the following steps: (a) impregnating the fabric in a desizing bath containing (as a minimum) an amylolytic enzyme hybrid and/or a lipolytic enzyme hybrid; (b) subjecting the impregnated fabric to steaming, so as to bring the fabric to the desired reaction temperature, gen- erally between 20° and 120°C; and (c) holding by rolling-up or pleating the cloth in a J-Box, U- Box, carpet machine or the like for a sufficient period of time (normally between a few minutes and several hours) to allow the desizing to occur. Prior to carrying out the chosen treatment, the amylolytic enzyme hybrid and/or the lipolytic enzyme hybrid may conveniently be mixed with other components which are conventionally used in the desizing process. Further components required for performance of the process may be added separately. Thus, for example, a wetting agent and, optionally, a stabilizer may be added. The stabilizer in question may be an agent stabilizing the amylolytic enzyme hybrid and/or the lipolytic enzyme hybrid. Wetting agents serve to improve the wettability of the fibre, whereby rapid and even desizing may be achieved. The wetting agent is preferably of an oxidation-stable type. In a preferred embodiment of the process of the invention, an amylolytic enzyme hybrid is used in an amount corresponding to an amylase activity in the range of between 1 and 5000 KNU per litre of desizing liquor, such as between 10 and 1000 KNU per litre of desizing liquor, preferably between 50 and 500 KNU per litre, more preferably between 20 and 500 KNU per litre of desizing liquor. In a preferred embodiment of the process of the invention, a lipolytic enzyme hybrid is used in an amount corresponding to a lipase activity in the range of between 10 and 20000 LU per litre of desizing liquor, such as between 50 and 10000 LU per litre of desizing liquor, more preferably between 100 and 5000 LU per litre of desizing liquor. Irrespective of the particular type of procedure to be used for the desizing, the process of the invention is normally performed at a temperature in the range of 30-100°C, such as 35-60°C, and at a pH in the range of 3-11, preferably 7-9. However, the actual process conditions may vary widely within these ranges. It will be understood that the process may be performed in any equipment sufficiently tolerant towards the process conditions in question. The process of the invention may be employed alone or in combination with one or more other enzymatic desizing processes. Suitable combinations include the following: a treatment with an amylolytic enzyme hybrid, and a treatment with a cellulase; a treatment with a lipolytic enzyme hybrid, and a treatment with a cellulase; a treatment with an amylolytic enzyme hybrid, and a treatment with a lipase or a lipolytic enzyme hybrid; a treatment with a lipolytic enzyme hybrid, and a treatment with an amylase or an amylolytic enzyme hybrid; a treatment with an amylolytic enzyme hybrid, and a treatment with a lipase or a lipolytic enzyme hybrid, and a treatment with a cellulase; a treatment with a lipolytic enzyme hybrid, and a treatment with an amylase or an amylolytic enzyme hybrid, and a treatment with a cellulase. The various enzymes/enzyme hybrids will normally be added in one step, but the desizing process may also be performed in more than one step, taking one enzyme/enzyme hybrid at a time. Composition of the invention Although an enzyme hybrid, e.g. amylolytic enzyme hybrid and/or lipolytic enzyme hybrid, may be added as such, it is preferred that it is formulated in the form of a suitable desizing composition. The desizing composition of the invention may comprise a single type of enzyme hybrid, or more than one type of enzyme hybrid (e.g. an amylolytic enzyme hybrid together with a lipolytic enzyme hybrid) . The composition may be in the form of, e.g., a granulate, preferably a non-dusting granulate, or a liquid, in particular a stabilized liquid, or a slurry, or in a protected form. Non-dusting granulates may be produced, for example, as disclosed in US 4,106,991 and US 4,661,452 (both to Novo Nordisk A/S) and may optionally be coated by methods known in the art . In the case of granular formulations ("granulates"), different enzyme hybrids may be formulated, for example, either as a single granulate wherein the individual granules each contain all the enzyme hybrids in question, or as a mixture of discrete, different granulates wherein the individual granules each contain one type of enzyme hybrid of the kind in question. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol (such as propylene glycol or another glycol) , a sugar, a sugar alcohol or acetic acid, according to established procedures. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared as disclosed in EP 238 216. The composition of the invention may comprise a wetting agent and/or, optionally, one or more further components selected from the group consisting of dispersing agents, sequestering agents (and/or precipitants) and emulsifying agents. An example of a suitable wetting agent is the commercial product Arbyl™ R, available from Grύnau, Germany. An emulsifying agent serves to emulsify hydrophobic impurities which may be present on the fabric. A dispersing agent serves to prevent the redeposition of extracted impurities on the fabric. A sequestering agent or precipitant serves to remove metal ions (such as Ca 2+ , Mg 2t and Fe 2+ ) which may have a negative impact on the process; suitable examples include caustic soda (sodium hydroxide) and soda ash (sodium carbonate) . A further aspect of the invention relates to a DNA construct disclosed herein which encodes, or which comprises a sequence which encodes, an enzyme hybrid as disclosed in the present specification. A still further aspect of the invention relates to a polypeptide (fusion protein or enzyme hybrid) which is encoded by such a DNA construct or sequence, and/or which is disclosed in the present specification. The invention is further illustrated by means of the examples given below, which are in no way intended ' _ limit the scope of the invention as claimed: MATERIALS AND METHODS Strains: Bacillus agaradherens NCIMB No. 40482: comprises the endoglucanase enzyme encoding DNA sequence of Example 2, below. Escherichia coli SJ2 [Diderichsen et al., J. Bacteriol. 172 (1990), pp. 4315-4321]. Electrocompetent cells prepared and transformed using a Bio- Rad GenePulser™ as recommended by the manufacturer. Bacillus subtilis PL2306: this strain is the B . subtilis DN1885 with disrupted apr and npr genes [Diderichsen et al., J. Bacteriol. 172 (1990) , pp. 4315-4321] disrupted in the transcriptional unit of the known Bacillus subtilis cellulase gene, resulting in cellulase-negative cells. The disruption was performed essentially as described in Sonenshein et al. (Eds.) , Bacillus subtilis and other Gram-Positive Bacteria. American Society for Microbiology (1993) , p.618. Plasmids: pDN1528 [Jørgensen et al . , J. Bacteriol. 173 (1991) , p.559-567] . pBluescriptKSII- (Stratagene, USA) . pDN1981 [Jørgensen et al. , Gene 96 (1990) , p37-41] Solutions/Media TY and LB agar [as described in Ausubel et al . (Eds.) , Current Protocols in Molecular Biology, John Wiley and Sons (1995) ] . SB: 32 g Tryptone, 20 g yeast extract, 5 g sodium chloride and 5 ml 1 N sodium hydroxide are mixed in sterile water to a final volume of 1 litre. The solution is sterilised by autoclaving for 20 minutes at 121°C. 10% Avicel™: 100 g of Avicel™ (FLUKA, Switzerland) is mixed with sterile water to a final volume of 1 litre, and the resulting 10% Avicel™ is sterilised by autoclaving for 20 minutes at 121"C. Buffer: 0.05 M potassium phosphate, pH 7.5. General molecular biology methods DNA manipulations and transformations were performed using standard methods of molecular biology [Sambrook et al. , Molecular Clonin : A Laboratory Manual, Cold Spring Harbor lab., Cold Spring Harbor, NY (1989) ; Ausubel et al . (Eds.) , Current Protocols in Molecular Biology. John Wiley and Sons (1995) ; CR. Harwood and S.M. Cutting (Eds.) Molecular Biological Methods for Bacillus, John Wiley and Sons (1990)] . Enzymes for DNA manipulations were used according to the specifications of the suppliers. EXAMPLE 1 Subcloning of a partial Teπnamyl sequence. The alfa-a ylase gene encoded on pDN1528 was PCR amplified for introduction of a BamHI site in the 3 ' -end of the coding region. The PCR and the cloning were carried out as follows: Approximately 10-20 ng of plasmid pDN1528 was PCR amplified in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix, and 300 pmol of each primer: #5289 5' -GCT TTA CGC CCG ATT GCT GAC GCT G -3' #26748 5 ' -GCG ATG AGA CGC GCG GCC GCC TAT CTT TGA ACA TAA ATT GAA ACG GAT CCG -3 ' (BamHI restriction site underlined] . The PCR reactions were performed using a DNA thermal cycler (Landgraf, Germany) . One incubation at 94°C for 2 min, 60°C for 30 sec and 72°C for 45 sec was followed by ten cycles of PCR performed using a cycle profile of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 45sec and twenty cycles of denaturation at 94°C for 30 sec, 60 'C for 30 sec and 72°C for 45 sec (at this elongation step, 20 sec are added every cycle) . 10 μl aliquots of amplification product were analyzed by electrophoresis in 1.0 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. 40 μl aliquots of PCR product generated as described above were purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5. 25 μl of the purified PCR fragment was digested with BamHI and PstI, subjected to electrophoresis in 1.0% low gelling temperature agarose (SeaPlaque™ GTG, FMC) gels, and the relevant fragment was excised from the gel and purified using QIAquick™ Gel extraction Kit (Qiagen, USA) according to the manufacturer's instructions. The isolated DNA fragment was then ligated to BamHI-PstI digested pBluescriptll KS- , and the ligation mixture was used to transform E. coli SJ2. Cells were plated on LB agar plates containing Ampicillin (200 μg/ml) and supplemented with X-gal (5-bromo-4-chloro-3- indolyl-α-D-galactopyranoside, 50 μg/ml) , and incubated at 37°C overnight. The next day, white colonies were restreaked onto fresh LB-Ampicillin agar plates and incubated at 37°C overnight. The following day, single colonies were transferred to liquid LB medium containing Ampicillin (200 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. 5 μl samples of the plasmids were digested with PstI and BamHI. The digestions were checked by gel electrophoresis on a 1.0% agarose gel (NuSie- ve™, FMC) . One positive clone, containing the PstI-BamHI fragment containing part of the α-amylase gene, was designated pMB335. This plasmid was then used in the construction of α-amylase-CBD hybrid. Isolation of genomic DNA Clostridium stercorarium NCIMB 11754 was grown anaerobically at 60°C in specified media as recommended by The National Collections of Industrial and Marine Bacteria Ltd. (NCIMB) , Scotland. Cells were harvested by centrifugation. Genomic DNA was isolated as described by Pitcher et al, Lett . APPI. Microbiol. 8 (1989) , pp. 151-156. In vitro amplification of the CBD-dimer of Clostridium Btercorarixim (NCIMB 11754) XynA Approximately 100-200 ng of genomic DNA was PCR amplified in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix, and 300 pmol of each primer: #27183 5 ' -GCT GCA GGA TCC GTT TCA ATT TAT GTT CAA AGA TCT GGC GGA CCT GGA ACG CCA AAT AAT GGA AGA GG -3 ' #27182 5' -GCA CTA GCT AGA CGG CCG CTA CCA GTC AAC ATT AAC AGG ACC TGA G -3' (BamHI and EagI restriction sites underlined) . The primers were designed to amplify the DNA encoding the cellulose-binding domain of the XynA-encoding gene of Clos tridium stercorarium NCIMB 11754; the DNA sequence was extracted from the database GenBank under the accession number D13325. The PCR reactions were performed using a DNA thermal cycler (Landgraf, Germany) . One incubation at 94°C for 2 min, 60°C for 30 sec and 72°C for 45 sec was followed by ten cycles of PCR performed using a cycle profile of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 45 sec and twenty cycles of denaturation at 94°C for 30 sec, 60 * C for 30 sec and 72°C for 45 sec (at this elongation step, 20 sec are added every cycle) . 10 μl aliquots of amplification product were analyzed by electrophoresis in 1.0 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. Cloning by polymerase chain reaction (PCR) : Subcloning of PCR fragments. 40 μl aliquots of PCR product generated as described above were purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5. 25 μl of the purified PCR fragment was digested with BamHI and EagI, subjected to electrophoresis in 1.0% low gelling temperature agarose (SeaPlaque™ GTG, FMC) gels, and the relevant fragment was excised from the gels and purified using QIAquick™ Gel extraction Kit (Qiagen, USA) according to the manufacturer's instructions. The isolated DNA fragment was then ligated to BamHI-NotI digested pMB335 and the ligation mixture was used to transform E. coli SJ2. Identification and characterization of positive clones Cells were plated on LB agar plates containing Ampicillin (200 μg/ml) and incubated at 37°C overnight. The next day, colonies were restreaked onto fresh LB-Ampicillin agar plates and incubated at 37°C overnight. The following day, single colonies were transferred to liquid LB medium containing Ampicillin (200 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. 5 μl samples of the plasmids were digested with BamHI and Notll. The digestions were checked by gel electrophoresis on a 1.0% agarose gel (NuSie- ve™, FMC) . The appearance of a DNA fragment of the same size as seen from the PCR amplification indicated a positive clone. One positive clone, containing the fusion construct of the α- amylase gene and the CBD-dimer of Clostridium stercorarium (NCIMB 11754) XynA, was designated MBamyX. Cloning of the fusion construct into a Bacillus-based expression vector The pDN1528 vector contains the amyL gene of B . licheniformis; this gene is actively expressed in B . subtilis, resulting in the production of active α-amylase appearing in the supernatant. For expression purposes, the DNA encoding the fusion protein as constructed above was introduced to pDN1528. This was done by digesting pMBamyX and pDN1528 with Sall- Notl, purifying the fragments and ligating the 4.7 kb pDN1528 SalI-NotI fragment with the 1.0 kb pMBamyX Sail-NotI fragment. This created an inframe fusion of the hybrid construction with the Termamyl™ (B . licheniformis α-amylase) gene. The DNA sequence of the fusion construction of pMB206, and the corresponding amino acid sequence, are shown in SEQ ID No. 1 and SEQ ID No. 2, respectively. The ligation mixture was used to transform competent cells of B. subtilis PL2306. Cells were plated on LB agar plates containing chloramphenicol (6 μg/ml) , 0.4% glucose and lOmM potassium hydrogen phosphate, and incubated at 37°C overnight. The next day, colonies were restreaked onto fresh LBPG (LB plates with 0.4% glucose and lOmM potassium phosphate, pH 10) chloramphenicol agar plates and incubated at 37°C overnight. The following day, single colonies of each clone were transferred to liquid LB medium containing chloramphenicol (6 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. However, the resuspension buffer was supplemented with 1 mg/ml of chicken egg white lysozyme (SIGMA, USA) prior to lysing the cells at 37°C for 15 minutes. 5 μl samples of the plasmids were digested with BamHI and NotI. The digestions were checked by gel electrophoresis on a 1.5% agarose gel (NuSieve™, FMC) . The appearance of a DNA fragment of the same size as seen from the PCR amplification indicated a positive clone. One positive clone was designated MB-BSamyx. Expression, secretion and functional analysis of the fusion protein The clone MB-BSamyx (expressing Termamyl™ fused to C. stercorarium XynA dimer CBD) was incubated for 20 hours in SB medium at 37°C with shaking at 250 rpm. 1 ml of cell-free supernatant was mixed with 200 μl of 10% Avicel™. The mixture was incubated for 1 hour at 0°C and then centrifuged for 5 minutes at 5000 x g. The pellet was resuspended in 100 μl of SDS-PAGE buffer, and the suspension was boiled at 95°C for 5 minutes, centrifuged at 5000 x g for 5 minutes, and 25 μl was loaded onto a 4-20% Laemmli Tris-Glycine, SDS-PAGE NOVEX™ gel (Novex, USA) . The samples were subjected to electrophoresis in an Xcell™ Mini-Cell (NOVEX, USA) as recommended by the manufacturer. All subsequent handling of gels, including staining (Coomassie) , destaining and drying, were performed as described by the manufacturer. The appearance of a protein band of molecular weight approx. 85 kDa indicated expression in B . subtilis of the Termamyl-CBD fusion amyx. EXAMPLE 2 Identification of a novel CBD representing a new CBD family The alkaline cellulase cloned in Bacillus subtilis as described below was expressed by incubating the clone for 20 hours in SB medium at 37°C with shaking at 250 rpm. The expressed cellulase was shown to contain a CBD by its ability to specifically bind to Avicel™. When left to incubate for a further 20 hours, the cellulase was proteolytically cleaved and two specific protein bands appeared in SDS-PAGE, one corresponding to the catalytic part of the cellulase, approximate molecular weight (MW) 35 kD, and the other corresponding to a proposed linker and CBD of approximate MW 8 kD. The CBD was found to be the C-terminal part of the cellulase, and did not match any of the CBD families described previously [Tomme et al., Cellulose-Binding Domains: Classification and Properties. In: J.N. Saddler and M.H. Penner (Eds.) , Enzymatic Degradation of Insoluble Carbohydrates, ACS Symposium Series No. 618 (1996)] . Accordingly, this CBD appears to be the first member of a new family. Cloning of the alkaline cellulase (endoglucanase) from Bacillus agaradherens and expression of the alkaline cellulase in Bacillus subtilis The nucleotide sequence encoding the alkaline cellulase from Bacill us agaradherens (deposited under accession No. NCIMB 40482) was cloned by PCR for introduction in an expression plasmid pDN1981. PCR was performed essentially as described above on 500 ng of genomic DNA, using the following two primers containing Ndel and Kpnl restriction sites for introducing the endoglucanase-encoding DNA sequence to pDN1981 for expression: #20887 5 ' -GTA GGC TCA GTC ATA TGT TAC ACA TTG AAA GGG GAG GAG AAT CAT GAA AAA GAT AAC TAC TAT TTT TGT CG-3' #21318 5 ' -GTA CCT CGC GGG TAC CAA GCG GCC GCT TAA TTG AGT GGT TCC CAC GGA CCG-3' After PCR cycling, the PCR fragment was purified using QIA¬ quick™ PCR column kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5, digested with Ndel and Kpnl, purified and ligated to digested pDN1981. The ligation mixture was used to transform B . subtilis PL2306. Competent cells were prepared and transformed as described by Yasbin et al . , J. Bacteriol. 121 (1975) , pp. 296-304. Isolation and testing of B. subtilis transformants The transformed cells were plated on LB agar plates containing Kanamycin (10 mg/ml) , 0.4% glucose, 10 mM potassium phosphate and 0.1% AZCL HE-cellulose (Megazyme, Australia) , and incubated at 37 °C for 18 hours. Endoglucanase-positive colonies were identified as colonies surrounded by a blue halo. Each of the positive transformants was inoculated in 10 ml TY medium containing Kanamycin (10 mg/ml) . After 1 day of incuba- tion at 37°C with shaking at 250rpm, 50 ml of supernatant was removed. The endoglucanase activity was identified by adding 50 ml of supernatant to holes punctured in the agar of LB agar plates containing 0.1% AZCL HE-cellulose. After 16 hours incubation at 37°C, blue halos surrounding holes indicated expression of the endoglucanase in B . subtilis . One such clone was designated MB208. The encoding DNA sequence and amino acid sequence of the endoglucanase are shown in SEQ ID No. 3 and SEQ ID No. 4, respectively. The DNA sequence was determined as follows: Qiagen purified plasmid DNA was sequenced with the Taq deoxy terminal cycle sequencing kit (Perkin Elmer, USA) using the primers #21318 and #20887 ( vide supra) and employing an Applied Biosystems 373A automated sequencer operated according to the manufac¬ turer's instructions. Analysis of the sequence data is performed according to Devereux et al., Carcinogenesis 14 (1993) , pp. 795-801. In vi tro amplification of the CBD of Bacillus agaradherens NCIMB 40482 endoglucanase Approximately 10-20 ng of plasmid pMB208 was PCR amplified in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix and 300 pmol of each primer: #27184 5 ' -GCT GCA GGA TCC GTT TCA ATT TAT GTT CAA AGA TCT CCT GGA GAG TAT CCA GCA TGG GAC CCA A-3 ' #28495 5'-GC ACA AGC TTG CGG CCG CTA ATT GAG TGG TTC CCA CGG ACC G ■ 3' (BamHI and NotI restriction sites underlined) . The primers were designed to amplify the CBD-encoding DNA of the cellulase-encoding gene of Bacillus agaradherens NCIMB 40482. The PCR reaction was performed using a DNA thermal cycler (Landgraf, Germany) . One incubation at 94°C for 2 min, 60°C for 30 sec and 72°C for 45 sec was followed by ten cycles of PCR performed using a cycle profile of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 45 sec and twenty cycles of denaturation at 94°C for 30 sec, 60 °C for 30 sec and 72°C for 45 sec (at this elongation step, 20 sec are added every cycle) . 10 μl aliquots of amplification product were analyzed by electrophoresis in 1.5 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. Cloning by polymerase chain reaction (PCR) : Subcloning of PCR fragments 40 μl aliquots of PCR products generated as described above were purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5. 25 μl of the purified PCR fragment was digested with BamHI and NotI, subjected to electrophoresis in 1.5% low gelling temperature agarose (SeaPlaque™ GTG, FMC) gels, and the relevant fragment was excised from the gels and purified using QIAquick™ Gel extraction kit (Qiagen, USA) according to the manufacturer's instructions. The isolated DNA fragment was then ligated to BamHI-NotI digested pMB335, and the ligation mixture was used to transform E. coli SJ2. Identification and characterization of positive clones Cells were plated on LB agar plates containing Ampicillin (200 μg/ml) and incubated at 37°C overnight. The next day, colonies were restreaked onto fresh LB-Ampicillin agar plates and incubated at 37°C overnight. The following day, single colonies were transferred to liquid LB medium containing Ampicillin (200 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. 5 μl samples of the plasmids were digested with BamHI and NotI. The digestions were checked by gel electrophoresis on a 1.5% agarose gel (NuSie- ve™, FMC) . The appearance of a DNA fragment of the same size as seen from the PCR amplification indicated a positive clone. One positive clone, containing the fusion construct of the Termamyl™ α-amylase gene and the CBD of Bacillus agaradherens NCIMB 40482 alkaline cellulase Cel5A, was designated MBamyC5A. Cloning of the fusion construct into a Bacillus-based expression vector As mentioned previously, the amyL gene of B . licheniformis (contained in the pDN1528 vector) is actively expressed in B . subtilis, resulting in the production of active α-amylase appearing in the supernatant. For expression purposes, the DNA encoding the fusion protein as constructed above was introduced to pDN1528. This was done by digesting pMBamyC5A and pDN1528 with Sail-NotI, purifying the fragments and ligating the 4.7 kb pDN1528 Sail-NotI fragment with the 0.5 kb pMBamyC5A Sall-NotI fragment. This created an inframe fusion of the hybrid construction with the Termamyl™ gene. The DNA sequence of the fusion construction of pMB378, and the corresponding amino acid sequence, are shown in SEQ ID No. 5 and SEQ ID No. 6, respectively. The ligation mixture was used to transform competent cells of B . subtilis PL2306. Cells were plated on LB agar plates containing chloramphenicol (6 μg/ml) , 0.4% glucose and lOmM potassium hydrogen phosphate, and incubated at 37°C overnight. The next day, colonies were restreaked onto fresh LBPG chloramphenicol agar plates and incubated at 37°C overnight. The following day, single colonies of each clone were transferred to liquid LB medium containing chloramphenicol (6 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. However, the resuspension buffer was supplemented with 1 mg/ml of chicken egg white lysozyme (SIGMA, USA) prior to lysing the cells at 37°C for 15 minutes. 5 μl samples of the plasmids were digested with BamHI and NotI. The digestions were checked by gel electrophoresis on a 1.5% agarose gel (NuSieve™, FMC) . The appearance of a DNA fragment of the same size as seen from the PCR amplification indicated a positive clone. One positive clone was designated MB378. Expression, secretion and functional analysis of the fusion protein The clone MB378 (expressing Termamyl™ fused to Bacillus agaradherens Cel5A CBD) was incubated for 20 hours in SB medium at 37°C with shaking at 250 rpm. 1 ml of cell-free supernatant was mixed with 200 μl of 10% Avicel™. The mixture was incubated for 1 hour at 0°C and then centrifuged for 5 minutes at 5000 x g. The pellet was resuspended in 100 μl of SDS-PAGE buffer, and the suspension was boiled at 95°C for 5 minutes, centrifuged at 5000 x g for 5 minutes, and 25 μl was loaded onto a 4-20% Laemmli Tris-Glycine, SDS-PAGE NOVEX™ gel (Novex, USA) . The samples were subjected to electrophoresis in an Xcell™ Mini-Cell (NOVEX, USA) as recommended by the manufacturer. All subsequent handling of gels, including staining (Coomassie) , destaining and drying, were performed as described by the manufacturer. The appearance of a protein band of molecular weight approx. 60 kDa indicated expression in B . subtilis of the Termamyl™- CBD fusion encoded on the plasmid pMB378. EXAMPLE 3 This example describes fusion of Termamyl™ and the CBD from Cellulomonas fi i (ATCC484) cenA gene using the sequence overlap extension (SOE) procedure [see, e.g., Sambrook et al. , Ausubel et al. , or CR. Harwood and S.M. Cutting ( loe . ci t . ) ] . The final construction is as follows: Termamyl™ promoter - Termamyl™ signal peptide - cenA CBD - linker - mature Termamyl™. Amplification of the Termamyl™ fragment for SOE Approximately 10-20 ng of plasmid pDN1528 was PCR amplified in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix, and 100 pmol of each primer: #4576 5' -CTC GTC CCA ATC GGT TCC GTC -3 " #28403 5' -TGC ACT GGT ACA GTT CCT ACA ACT AGT CCT ACA CGT GCA AAT CTT AAT GGG ACG CTG -3 ' The part of the primer #28403 constituting a fragment of the Termamyl™ sequence is underlined. The sequence on the 5' side of this underlined sequence is that coding for the linker region to the CBD. The PCR reaction was performed using a DNA thermal cycler (Landgraf, Germany) . One incubation at 94°C for 2 min, 55°C for 30 sec and 72°C for 45 sec was followed by twenty cycles of PCR performed using a cycle profile of denaturation at 96°C for 10 sec, annealing at 55°C for 30 sec, and extension at 72°C for 45 sec. 10 μl aliquots of the amplification pro- duct were analyzed by electrophoresis in 1.0 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. 40 μl aliquots of the PCR product generated as described above were purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5. Isolation of genomic DNA Cellulomonas fimi ATCC484 was grown in TY medium at 30°C with shaking at 250 rpm for 24 hours. Cells were harvested by centrifugation. Genomic DNA was isolated as described by Pitcher et al. , Lett. APPI. Microbiol. 8 (1989) , pp. 151-156. In vi tro amplification of the CBD of Cellulomonas fimi (ATCC484) cenA gene for SOE procedure Approximately 100-200 ng of genomic DNA was PCR amplified in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix, and 100 pmol of each primer: #8828 5' -CTG CCT CAT TCT GCA GCA GCG GCG GCA AAT CTT AAT GCT CCC GGC TGC CGC GTC GAC TAC -3 ' #28404 5' -TGT AGG AAC TGT ACC AGT GCA CGT GGT GCC GTT GAG C -3' (PstI restriction site underlined) . The primers were designed to amplify the DNA encoding the cellulose-binding domain of the CenA-encoding gene of Cellulomonas fimi (ATCC484) . The DNA sequence was extracted from the database GenBank under the accession number M15823. PCR cycling was performed as follows: One incubation at 94°C for 2 min, 55°C for 30 sec and 72°C for 45 sec was followed by thirty cycles of PCR performed using a cycle profile of denaturation at 96°C for 10 sec, annealing at 55°C for 30 sec, and extension at 72°C for 45 sec. 10 μl aliquots of the amplification product were analyzed by electrophoresis in 1.0 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. 40 μl aliquots of the PCR product generated as described above were purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified DNA was eluted in 50 μl of lOmM Tris-HCl, pH 8 . 5 . SOE of the CBD from Cellulomonas fimi (ATCC484) cenA gene and the Termamyl™ gene Approximately 100-200 ng of the PCR amplified Termamyl™ fragment and the PCR amplified cenA CBD fragment were used in a second round of PCR. SOE of the two fragments was performed in in HiFidelity™ PCR buffer (Boehringer Mannheim, Germany) supplemented with 200 μM of each dNTP, 2.6 units of HiFidelity™ Expand enzyme mix. A touch-down PCR cycling was performed as follows: One incubation at 96°C for 2 min, 60°C for 2 min and 72°C for 45 sec. This cycle was repeated ten times with a 1°C decrease of the annealing temperature at each cycle. A third PCR reaction was started by adding 100 pmol of the two flanking primers #8828 and #4576 ( vide supra) to amplify the hybrid DNA. PCR was performed by incubating the SOE reaction mixture at 96°C for 2 min, 55°C for 30 sec and 72°C for 45 sec. This was followed by twenty cycles of PCR performed using a cycle profile of denaturation at 96°C for 10 sec, annealing at 55 ° C for 30 sec, and extension at 72°C for 45 sec. 10 μl aliquots of the amplification product were analyzed by electrophoresis in 1.0 % agarose gels (NuSieve™, FMC) with ReadyLoad™ lOObp DNA ladder (GibcoBRL, Denmark) as a size marker. The SOE fragment had the expected size of 879 bp. Subcloning of the SOE fragment coding for the CBD-Termamyl hybrid 40 μl of the SOE-PCR product generated as described above was purified using QIAquick™ PCR purification kit (Qiagen, USA) according to the manufacturer's instructions. The purified D- NA was eluted in 50 μl of lOmM Tris-HCl, pH 8.5. 25 μl of the purified PCR fragment was digested with PstI and Kpnl, subjected to electrophoresis in 1.0% low gelling temperature agarose (SeaPlaque™ GTG, FMC) gels, and a fragment of 837 bp was excised from the gel and purified using QIAquick™ Gel extraction Kit (Qiagen, USA) according to the manufacturer's instructions. The isolated DNA fragment was then ligated to PstI- and Kpnl-digested pDN1981, and the ligation mixture was used to transform competent cells of J3. subtilis PL2306. Cells were plated on LB agar plates containing Kanamycin (10 μg/ml) , 0.4% glucose and lOmM potassium hydrogen phosphate, and incubated at 37°C overnight. The next day, colonies were restreaked onto fresh LBPG Kanamycin agar plates and in¬ cubated at 37°C overnight. The following day, single colonies of each clone were transferred to liquid LB medium containing Kanamycin (10 μg/ml) and incubated overnight at 37°C with shaking at 250 rpm. Plasmids were extracted from the liquid cultures using QIAgen Plasmid Purification mini kit (Qiagen, USA) according to the manufacturer's instructions. However, the resuspension buffer was supplemented with 1 mg/ml of chicken egg white lysozyme (SIGMA, USA) prior to lysing the cells at 37°C for 15 minutes. 5 μl samples of the plasmids were digested with PstI and Kpnl. The digestions were checked by gel electrophoresis on a 1.5% agarose gel (NuSieve™, FMC) . The appearance of a DNA fragment of 837 bp, the same size as seen from the PCR amplification, indicated a positive clone. One positive clone was designated MOL1297. Expression, secretion and functional analysis of the fusion protein The clone MOL1297 (expressing C. fimi cenA CBD fused to the N-terminal of Termamyl™) was incubated for 20 hours in SB medium at 37°C with shaking at 250 rpm. 1 ml of cell-free supernatant was mixed with 200 μl of 10% Avicel™. The mixture was incubated for 1 hour at 0°C and then centrifuged for 5 min at 5000 x g. The pellet was resuspended in 100 μl of SDS-PAGE buffer, boiled at 95°C for 5 minutes, centrifuged at 5000 x g for 5 minutes, and 25 μl was loaded on a 4-20% Laemmli Tris-Glycine, SDS-PAGE NOVEX gel (Novex, USA) . The samples were subjected to electrophoresis in an Xcell™ Mini- Cell (NOVEX, USA) as recommended by the manufacturer. All subsequent handling of gels including staining (Coomassie) , destaining and drying, was performed as described by the manufacturer. The appearance of a protein band of MW approx. 85 kDa indicated expression in B . subtilis of the CBD-Termamyl™ fusion. The encoding sequence for the C. fimi cenA CBD-Termamyl hybrid is shown in SEQ ID No. 7 (in which lower case letters indicate the CBD-encoding part of the sequence) . The corresponding amino acid sequence of the hybrid is shown in SEQ ID No. 8 (in which lower case letters indicate the CBD amino acid sequence) . EXAMPLE 4 This example describes the construction of fusion proteins (enzyme hybrid) from a lipase (Lipolase™; Humicola lanuginosa lipase) and a CBD. A construction with an N- terminal CBD was chosen, since the N-terminal of the enzyme is far from the active site, whereas the C-terminal is in relatively close proximity to the active site. pIVI450 construction (CBD-linker-lipase) This construct was made in order to express a protein having the Myceliophthora thermophila cellulase CBD and linker at the N-terminal of Lipolase™. A PCR fragment was created using the clone pA2C161 (DSM 9967) containing the M. thermophila cellulase gene as template, and the following oligomers as primers: #8202 5 ' ACGTAGTGGCCACGCTAGGCGAGGTGGTGG #19672 5* CCACACTTCTCTTCCTTCCTC 3 ' The PCR fragment was cut with BamHI and Ball, and cloned into pAHL which was also cut with BamHI and Ball just upstream of the presumed signal peptide processing site. The cloning was verified by sequencing (see SEQ ID No. 9) . Removing linker between CBD and lipase This construct is made so that any linker of interest can be inserted between the CBD and the lipase in order to find an optimal linker. An Nhel site is introduced by the USE technique (Stratagene catalogue No. 200509) between the CBD and linker region in pIVI450, creating pIVI450+NheI site. pIVI450+NheI site is cut with Xhol and Nhel, isolating the vector containing the CBD part . The plasmid pIVI392 is cut with Xhol and Nhel, and the fragment containing the Lipolase™ gene (minus signal peptide encoding sequence) is isolated. The DNA fragments are ligated, generating pIVI450 CBD-Nhel site-Lipolase™ containing an Nhel site between the CBD and the lipase gene. In this Nhel site different linkers can be introduced. Introduction of non-glycosylated linker The protein expressed from the construct described here contains a construction of the type: CBD-nonglycosylated linker-lipase. The amino acid sequence of the linker is as follows: NNNPQQGNPNQGGNNGGGNQGGGNGG PCR is performed with the following primers: #29315 5 ' GATCTAGCTAGCAACAATAACCCCCAGCAGGGCAACCCCAACCAGGGC GGGAACAACGGC 3 ' #29316 5 ' GATCTAGCTAGCGCCGCCGTTGCCGCCGCCCTGGTTGCCGCCGCCGTT GTTCCCGCCCTG 3 ' The PCR fragment is cut with Nhel, the vector pIVI450 CBD- Nhel-Lipolase™ is likewise cut with Nhel, and the two fragments are ligated, creating: pIVI450 CBD-Nonglycosylated linker-Lipolase™ (SEQ ID No. 10 ) . Introduction of H. insolens family 45 cellulase linker The protein expressed from the construct described here contains a construction of the type: CBD-glycosylated linker-lipase. The amino acid sequence of the linker is as follows: VQIPSSSTSSPVNQPTSTSTTSTSTTSSPPVQPTTPS PCR is performed with the following primers: #29313 5' GATACTGCTAGCGTCCAGATCCCCTCCAGC 3' #29314 5' GATACTGCTAGCGCTGGGAGTCGTAGGCTG 3' The PCR fragment is cut with Nhel, the vector pIVI450 CBD- Nhel-Lipolase™ is likewise cut with Nhel, and the two fragments are ligated, creating: pIVI450 CBD-H. insolens family 45 cellulase linker-Lipolase™ (SEQ ID No. 11) . SEQUENCE LISTING (1) GENERAL INFORMATION: <i) APPLICANT: (A) NAME: NOVO NORDISK A/S (B) STREET: Novo Alle (C) CITY: Bagsvaerd (E) COUNTRY: Denmark (F) POSTAL CODE (ZIP) : DK-2880 (G) TELEPHONE: +45 44 44 88 88 (H) TELEFAX: +45 44 49 32 56 (ii) TITLE OF INVENTION: PROCESS FOR REMOVAL OR BLEACHING OF SOILING OR STAINS FROM CELLULOSIC FABRIC (iii) NUMBER OF SEQUENCES: 6 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2253 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: ATGAAACAAC AAAAACGGCT TTACGCCCGA TTGCTGACGC TGTTATTTGC GCTCATCTTC 60 TTGCTGCCTC ATTCTGCAGC AGCGGCGGCA AATCTTAATG GGACGCTGAT GCAGTATTTT 120 GAATGGTACA TGCCCAATGA CGGCCAACAT TGGAAGCGTT TGCAAAACGA CTCGGCATAT 180 TTGGCTGAAC ACGGTATTAC TGCCGTCTGG ATTCCCCCGG CATATAAGGG AACGAGCCAA 240 GCGGATGTGG GCTACGGTGC TTACGACCTT TATGATTTAG GGGAGTTTCA TCAAAAAGGG 300 ACGGTTCGGA CAAAGTACGG CACAAAAGGA GAGCTGCAAT CTGCGATCAA AAGTCTTCAT 360 TCCCGCGACA TTAACGTTTA CGGGGATGTG GTCATCAACC ACAAAGGCGG CGCTGATGCG 420 ACCGAAGATG TAACCGCGGT TGAAGTCGAT CCCGCTGACC GCAACCGCGT AATCTCAGGA 480 GAACACCTAA TTAAAGCCTG GACACATTTT CATTTTCCGG GGGCCGGCAG CACATACAGC 540 GATTTTAAAT GGCATTGGTA CCATTTTGAC GGAACCGATT GGGACGAGTC CCGAAAGCTG 600 AACCGCATCT ATAAGTTTCA AGGAAAGGCT TGGGATTGGG AAGTTTCCAA TGAAAACGGC 660 AACTATGATT ATTTGATGTA TGCCGACATC GATTATGACC ATCCTGATGT CGCAGCAGAA 720 ATTAAGAGAT GGGGCACTTG GTATGCCAAT GAACTGCAAT TGGACGGAAA CCGTCTTGAT 780 GCTGTCAAAC ACATTAAATT TTCTTTTTTG CGGGATTGGG TTAATCATGT CAGGGAAAAA 840 ACGGGGAAGG AAATGTTTAC GGTAGCTGAA TATTGGCAGA ATGACTTGGG CGCGCTGGAA 900 AACTATTTGA ACAAAACAAA TTTTAATCAT TCAGTGTTTG ACGTGCCGCT TCATTATCAG 960 TTCCATGCTG CATCGACACA GGGAGGCGGC TATGATATGA GGAAATTGCT GAACGGTACG 1020 GTCGTTTCCA AGCATCCGTT GAAATCGGTT ACATTTGTCG ATAACCATGA TACACAGCCG 1080 GGGCAATCGC TTGAGTCGAC TGTCCAAACA TGGTTTAAGC CGCTTGCTTA CGCTTTTATT 1140 CTCACAAGGG AATCTGGATA CCCTCAGGTT TTCTACGGGG ATATGTACGG GACGAAAGGA 1200 GACTCCCAGC GCGAAATTCC TGCCTTGAAA CACAAAATTG AACCGATCTT AAAAGCGAGA 1260 AAACAGTATG CGTACGGAGC ACAGCATGAT TATTTCGACC ACCATGACAT TGTCGGCTGG 1320 ACAAGGGAAG GCGACAGCTC GGTTGCAAAT TCAGGTTTGG CGGCATTAAT AACAGACGGA 1380 CCCGGTGGGG CAAAGCGAAT GTATGTCGGC CGGCAAAACG CCGGTGAGAC ATGGCATGAC 1440 ATTACCGGAA ACCGTTCGGA GCCGGTTGTC ATCAATTCGG AAGGCTGGGG AGAGTTTCAC 1500 GTAAACGGCG GATCCGTTTC AATTTATGTT CAAAGATCTG GCGGACCTGG AACGCCAAAT 1560 AATGGCAGAG GAATTGGTTA TATTGAAAAT GGTAATACCG TAACTTACAG CAATATAGAT 1620 TTTGGTAGTG GTGCAACAGG GTTCTCTGCA ACTGTTGCAA CGGAGGTTAA TACCTCAATT 1680 CAAATCCGTT CTGACAGTCC TACCGGAACT CTACTTGGTA CCTTATATGT AAGTTCTACC 1740 GGCAGCTGGA ATACATATCA ACCGTATCTA CAAACATCAG CAAAATTACC GGCGTTCATG 1800 ATATTGTATT GGTATTCTCA GGTCCAGTCA ATGTGGACAA CTTCATATTT AGCAGAAGTT 1860 CACCAGTGCC TGCACCTGGT GATAACACAA GAGACGCATA TTCTATCATT CAGGCCGAGG 1920 ATTATGACAG CAGTTATGGT CCCAACCTTC AAATCTTTAG CTTACCAGGT GGTGGCAGCG 1980 CTTGGCTATA TTGAAAATGG TTATTCCACT ACCTATAAAA ATATTGATTT TGGTGACGGC 2040 GCAACGTCCG TAACAGCAAG AGTAGCTACC CAGAATGCTA CTACCATTCA GGTAAGATTG 2100 GGAAGTCCAT CGGGTACATT ACTTGGAACA ATTTACGTGG GGTCCACAGG AAGCTTTGAT 2160 ACTTATAGGG ATGTATCCGC TACCATTAGT AATACTGCGG GTGTAAAAGA TATTGTTCTT 2220 GTATTCTCAG GTCCTGTTAA TGTTGACTGG TAG 2253 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 750 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Lys Gin Gin Lys Arg Leu Tyr Ala Arg Leu Leu Thr Leu Leu Phe 1 5 10 15 Ala Leu Ile Phe Leu Leu Pro His Ser Ala Ala Ala Ala Ala Asn Leu 20 25 30 Asn Gly Thr Leu Met Gin Tyr Phe Glu Trp Tyr Met Pro Asn Asp Gly 35 40 45 Gin His Trp Lys Arg Leu Gin Asn Asp Ser Ala Tyr Leu Ala Glu His 50 55 60 Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Thr Ser Gin 65 70 75 80 Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe 85 90 95 His Gin Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Gly Glu Leu 100 105 110 Gin Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly 115 120 125 Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val 130 135 140 Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly 145 150 155 160 Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Ala Gly 165 170 175 Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr 180 185 190 Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gin Gly 195 200 205 Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn Tyr Asp Tyr 210 215 220 Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val Ala Ala Glu 225 230 235 240 Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gin Leu Asp Gly 245 250 255 Asn Arg Leu Asp Ala Val Lys His lie Lys Phe Ser Phe Leu Arg Asp 260 265 270 Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met Phe Thr Val 275 280 285 Ala Glu Tyr Trp Gin Asn Asp Leu Gly Ala Leu Glu Asn Tyr Leu Asn 290 295 300 Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu His Tyr Gin 305 310 315 320 Phe His Ala Ala Ser Thr Gin Gly Gly Gly Tyr Asp Met Arg Lys Leu 325 330 335 Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser Val Thr Phe 340 345 350 Val Asp Asn His Asp Thr Gin Pro Gly Gin Ser Leu Glu Ser Thr Val 355 360 365 Gin Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu Thr Arg Glu 370 375 380 Ser Gly Tyr Pro Gin Val Phe Tyr Gly Asp Met Tyr Gly Thr Lys Gly 385 390 395 400 Asp Ser Gin Arg Glu Ile Pro Ala Leu Lys His Lys Ile Glu Pro Ile 405 410 415 Leu Lys Ala Arg Lys Gin Tyr Ala Tyr Gly Ala Gin His Asp Tyr Phe 420 425 430 Asp His His Asp Ile Val Gly Trp Thr Arg Glu Gly Asp Ser Ser Val 435 440 445 Ala Asn Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ala 450 455 43'' Lys Arg Met Tyr Val Gly Arg Gin Asn Ala Gly Glu Thr Trp His Asp 465 470 475 480 Ile Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser Glu Gly Trp 485 490 495 Gly Glu Phe His Val Asn Gly Gly Ser Val Ser Ile Tyr Val Gin Arg 500 505 510 Ser Gly Gly Pro Gly Thr Pro Asn Asn Gly Arg Gly Ile Gly Tyr Ile 515 520 525 Glu Asn Gly Asn Thr Val Thr Tyr Ser Asn Ile Asp Phe Gly Ser Gly 530 535 540 Ala Thr Gly Phe Ser Ala Thr Val Ala Thr Glu Val Asn Thr Ser Ile 545 550 555 560 Gin lie Arg Ser Asp Ser Pro Thr Gly Thr Leu Leu Gly Thr Leu Tyr 565 570 575 Val Ser Ser Thr Gly Ser Trp Asn Thr Tyr Gin Pro Tyr Leu Gin Thr 580 585 590 Ser Ala Lys Leu Pro Ala Phe Met Ile Leu Tyr Trp Tyr Ser Gin Val 595 600 605 Gin Ser Met Trp Thr Thr Ser Tyr Leu Ala Glu Val His Gin Cys Leu 610 615 620 His Leu Val Ile.Thr Gin Glu Thr His Ile Leu Ser Phe Arg Pro Arg 625 630 635 640 Ile Met Thr Ala Val Met Val Pro Thr Phe Lys Ser Leu Ala Tyr Gin 645 650 655 Val Val Ala Ala Leu Gly Tyr Ile Glu Asn Gly Tyr Ser Thr Thr Tyr 660 665 670 Lys Asn Ile Asp Phe Gly Asp Gly Ala Thr Ser Val Thr Ala Arg Val 675 680 685 Ala Thr Gin Asn Ala Thr Thr Ile Gin Val Arg Leu Gly Ser Pro Ser 690 695 700 Gly Thr Leu Leu Gly Thr Ile Tyr Val Gly Ser Thr Gly Ser Phe Asp 705 710 715 720 Thr Tyr Arg Asp Val Ser Ala Thr Ile Ser Asn Thr Ala Gly Val Lys 725 730 735 Asp Ile Val Leu Val Phe Ser Gly Pro Val Asn Val Asp Trp 740 745 750 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1203 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: ATGAAAAAGA TAACTACTAT TTTTGTCGTA TTGCTTATGA CAGTGGCGTT GTTCAGTATA 60 GGAAACACGA CTGCTGCTGA TAATGATTCA GTTGTAGAAG AACATGGGCA ATTAAGTATT 120 AGTAACGGTG AATTAGTCAA TGAACGAGGC GAACAAGTTC AGTTAAAAGG GATGAGTTCC 180 CATGGTTTGC AATGGTACGG TCAATTTGTA AACTATGAAA GTATGAAATG GCTAAGAGAT 240 GATTGGGGAA TAAATGTATT CCGAGCAGCA ATGTATACCT CTTCAGGAGG ATATATTGAT 300 GATCCATCAG TAAAGGAAAA AGTAAAAGAG GCTGTTGAAG CTGCGATAGA CCTTGATATA 360 TATGTGATCA TTGATTGGCA TATCCTTTCA GACAATGACC CAAATATATA TAAAGAAGAA 420 GCGAAGGATT TCTTTGATGA AATGTCAGAG TTGTATGGAG ACTATCCGAA TGTGATATAC 480 GAAATTGCAA ATGAACCGAA TGGTAGTGAT GTTACGTGGG GCAATCAAAT AAAACCGTAT 540 GCAGAGGAAG TCATTCCGAT TATTCGTAAC AATGACCCTA ATAACATTAT TATTGTAGGT 600 ACAGGTACAT GGAGTCAGGA TGTCCATCAT GCAGCTGATA ATCAGCTTGC AGATCCTAAC 660 GTCATGTATG CATTTCATTT TTATGCAGGG ACACATGGTC AAAATTTACG AGACCAAGTA 720 GATTATGCAT TAGATCAAGG AGCAGCGATA TTTGTTAGTG AATGGGGAAC AAGTGCAGCT 780 ACAGGTGATG GTGGCGTGTT TTTAGATGAA GCACAAGTGT GGATTGACTT TATGGATGAA 840 AGAAATTTAA GCTGGGCCAA CTGGTCTCTA ACGCATAAAG ATGAGTCATC TGCAGCGTTA 900 ATGCCAGGTG CAAATCCAAC TGGTGGTTGG ACAGAGGCTG AACTATCTCC ATCTGGTACA 960 TTTGTGAGGG AAAAAATAAG AGAATCAGCA TCTATTCCGC CAAGCGATCC AACACCGCCA 1020 TCTGATCCAG GAGAACCGGA TCCAACGCCC CCAAGTGATC CAGGAGAGTA TCCAGCATGG 1080 GATCCAAATC AAATTTACAC AAATGAAATT GTGTACCATA ACGGCCAGCT ATGGCAAGCA 1140 AAATGGTGGA CACAAAATCA AGAGCCAGGT GACCCGTACG GTCCGTGGGA ACCACTCAAT 1200 TAA 1203 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Met Lys Lys Ile Thr Thr Ile Phe Val Val Leu Leu Met Thr Val Ala 1 5 10 15 Leu Phe Ser Ile Gly Asn Thr Thr Ala Ala Asp Asn Asp Ser Val Val 20 25 30 Glu Glu His Gly Gin Leu Ser Ile Ser Asn Gly Glu Leu Val Asn Glu 35 40 45 Arg Gly Glu Gin Val Gin Leu Lys Gly Met Ser Ser His Gly Leu Gin 50 55 60 Trp Tyr Gly Gin Phe Val Asn Tyr Glu Ser Met Lys Trp Leu Arg Asp 65 70 75 80 Asp Trp Gly Ile Asn Val Phe Arg Ala Ala Met Tyr Thr Ser Ser Gly 85 90 95 Gly Tyr Ile Asp Asp Pro Ser Val Lys Glu Lys Val Lys Glu Ala Val 100 105 110 Glu Ala Ala Ile Asp Leu Asp Ile Tyr Val Ile Ile Asp Trp His Ile 115 120 125 Leu Ser Asp Asn Asp Pro Asn Ile Tyr Lys Glu Glu Ala Lys Asp Phe 130 135 140 Phe Asp Glu Met Ser Glu Leu Tyr Gly Asp Tyr Pro Asn Val Ile Tyr 145 150 155 160 Glu Ile Ala Asn Glu Pro Asn Gly Ser Asp Val Thr Trp Gly Asn Gin 165 170 175 Ile Lys Pro Tyr Ala Glu Glu Val lie Pro Ile Ile Arg Asn Asn Asp 180 185 190 Pro Asn Asn Ile Ile Ile Val Gly Thr Gly Thr Tcp £•=- Gin Asp Val 195 200 205 His His Ala Ala Asp Asn Gin Leu Ala Asp Pro Asn Val Met Tyr Ala 210 215 220 Phe His Phe Tyr Ala Gly Thr His Gly Gin Asn Leu Arg Asp Gin Val 225 230 235 240 Asp Tyr Ala Leu Asp Gin Gly Ala Ala Ile Phe Val Ser Glu Trp Gly 245 250 255 Thr Ser Ala Ala Thr Gly Asp Gly Gly Val Phe Leu Asp Glu Ala Gin 260 265 270 Val Trp Ile Asp Phe Met Asp Glu Arg Asn Leu Ser Trp Ala Asn Trp 275 280 285 Ser Leu Thr His Lys Asp Glu Ser Ser Ala Ala Leu Met Pro Gly Ala 290 295 300 Asn Pro Thr Gly Gly Trp Thr Glu Ala Glu Leu Ser Pro Ser Gly Thr 305 310 315 320 Phe Val Arg Glu Lys Ile Arg Glu Ser Ala Ser Ile Pro Pro Ser Asp 325 330 335 Pro Thr Pro Pro Ser Asp Pro Gly Glu Pro Asp Pro Thr Pro Pro Ser 340 345 350 Asp Pro Gly Glu Tyr Pro Ala Trp Asp Pro Asn Gin Ile Tyr Thr Asn 355 360 365 Glu Ile Val Tyr His Asn Gly Gin Leu Trp Gin Ala Lys Trp Trp Thr 370 375 380 Gin Asn Gin Glu Pro Gly Asp Pro Tyr Gly Pro Trp Glu Pro Leu Asn 385 390 395 400 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1683 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: ATGAAACAAC AAAAACGGCT TTACGCCCGA TTGCTGACGC TGTTATTTGC GCTCATCTTC 60 TTGCTGCCTC ATTCTGCAGC AGCGGCGGCA AATCTTAATG GGACGCTGAT GCAGTATTTT 120 GAATGGTACA TGCCCAATGA CGGCCAACAT TGGAAGCGTT TGCAAAACGA CTCGGCATAT 180 TTGGCTGAAC ACGGTATTAC TGCCGTCTGG ATTCCCCCGG CATATAAGGG AACGAGCCAA 240 GCGGATGTGG GCTACGGTGC TTACGACCTT TATGATTTAG GGGAGTTTCA TCAAAAAGGG 300 ACGGTTCGGA CAAAGTACGG CACAAAAGGA GAGCTGCAAT CTGCGATCAA AAGTCTTCAT 360 TCCCGCGACA TTAACGTTTA CGGGGATGTG GTCATCAACC ACAAAGGCGG CGCTGATGCG 420 ACCGAAGATG TAACCGCGGT TGAAGTCGAT CCCGCTGACC GCAACCGCGT AATCTCAGGA 480 GAACACCTAA TTAAAGCCTG GACACATTTT CATTTTCCGG GGGCCGGCAG CACATACAGC 540 GATTTTAAAT GGCATTGGTA CCATTTTGAC GGAACCGATT GGGACGAGTC CCGAAAGCTG 600 AACCGCATCT ATAAGTTTCA AGGAAAGGCT TGGGATTGGG AAGTTTCCAA TGAAAACGGC 660 AACTATGATT ATTTGATGTA TGCCGACATC GATTATGACC ATCCTGATGT CGCAGCAGAA 720 ATTAAGAGAT GGGGCACTTG GTATGCCAAT GAACTGCAAT TGGACGGAAA CCGTCTTGAT 780 GCTGTCAAAC ACATTAAATT TTCTTTTTTG CGGGATTGGG TTAATCATGT CAGGGAAAAA 840 ACGGGGAAGG AAATGTTTAC GGTAGCTGAA TATTGGCAGA ATGACTTGGG CGCGCTGGAA 900 AACTATTTGA ACAAAACAAA TTTTAATCAT TCAGTGTTTG ACGTGCCGCT TCATTATCAG 960 TTCCATGCTG CATCGACACA GGGAGGCGGC TATGATATGA GGAAATTGCT GAACGGTACG 1020 GTCGTTTCCA AGCATCCGTT GAAATCGGTT ACATTTGTCG ATAACCATGA TACACAGCCG 1080 GGGCAATCGC TTGAGTCGAC TGTCCAAACA TGGTTTAAGC CGCTTGCTTA CGCTTTTATT 1140 CTCACAAGGG AATCTGGATA CCCTCAGGTT TTCTACGGGG ATATGTACGG GAC VJ-AGGA 1200 GACTCCCAGC GCGAAATTCC TGCCTTGAAA CACAAAATTG AACCGi^CTT .-ΛAAGCGAGA 1260 AAACAGTATG CGTACGGAGC ACAGCATGAT TATTTCGACC ACCATGACAT TGTCGGCTGG 1320 ACAAGGGAAG GCGACAGCTC GGTTGCAAAT TCAGGTTTGG CGGCATTAAT AACAGACGGA 1380 CCCGGTGGGG CAAAGCGAAT GTATGTCGGC CGGCAAAACG CCGGTGAGAC ATGGCATGAC 1440 ATTACCGGAA ACCGTTCGGA GCCGGTTGTC ATCAATTCGG AAGGCTGGGG AGAGTTTCAC 1500 GTAAACGGCG GATCCGTTTC AATTTATGTT CAAAGATCTC CTGGAGAGTA TCCAGCATGG 1560 GATCCAAATC AAATTTACAC AAATGAAATT GTGTACCATA ACGGCCAGCT ATGGCAAGCA 1620 AAATGGTGGA CACAAAATCA AGAGCCAGGT GACCCGTACG GTCCGTGGGA ACCACTCAAT 1680 TAA 1683 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 560 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Lys Gin Gin Lys Arg Leu Tyr Ala Arg Leu Leu Thr Leu Leu Phe 1 5 10 15 Ala Leu Ile Phe Leu Leu Pro His Ser Ala Ala Ala Ala Ala Asn Leu 20 25 30 Asn Gly Thr Leu Met Gin Tyr Phe Glu Trp Tyr Met Pro Asn Asp Gly 35 40 45 Gin His Trp Lys Arg Leu Gin Asn Asp Ser Ala Tyr Leu Ala Glu His 50 55 60 Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Thr Ser Gin 65 70 75 80 Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu Gly Glu Phe 85 90 95 His Gin Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Gly Glu Leu 100 105 110 Gin Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn Val Tyr Gly 115 120 125 Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr Glu Asp Val 130 135 140 Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val Ile Ser Gly 145 150 155 160 Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro Gly Ala Gly 165 170 175 Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly Thr 180 185 190 Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys Phe Gin Gly 195 200 205 Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn Tyr Asp Tyr 210 215 220 Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val Ala Ala Glu 225 230 235 240 lie Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gin Leu Asp Gly 245 250 255 Asn Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe Leu Arg Asp 260 265 270 Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met Phe Thr Val 275 280 285 Ala Glu Tyr Trp Gin Asn Asp Leu Gly Ala Leu Glu Asn Tyr Leu Asn 290 295 300 Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu His Tyr Gin 305 310 315 320 Phe His Ala Ala Ser Thr Gin Gly Gly Gly Tyr Asp Met Arg Lys Leu 325 330 335 Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser Val Thr Phe 340 345 350 Val Asp Asn His Asp Thr Gin Pro Gly Gin Ser Leu Glu Ser Thr Val 355 360 365 Gin Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu Thr Arg Glu 370 375 380 Ser Gly Tyr Pro Gin Val Phe Tyr Gly Asp Met Tyr Gly Thr Lys Gly 385 390 395 400 Asp Ser Gin Arg Glu Ile Pro Ala Leu Lys His Lys Ile Glu Pro Ile 405 410 415 Leu Lys Ala Arg Lys Gin Tyr Ala Tyr Gly Ala Gin His Asp Tyr Phe 420 425 430 Asp His His Asp Ile Val Gly Trp Thr Arg Glu Gly Asp Ser Ser Val 435 440 445 Ala Asn Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ala 450 455 460 Lys Arg Met Tyr Val Gly Arg Gin Asn Ala Gly Glu Thr Trp His Asp 465 470 475 480 Ile Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser Glu Gly Trp 485 490 495 Gly Glu Phe His Val Asn Gly Gly Ser Val Ser lie Tyr Val Gin Arg 500 505 510 Ser Pro Gly Glu Tyr Pro Ala Trp Asp Pro Asn Gin Ile Tyr Thr Asn 515 520 525 Glu Ile Val Tyr His Asn Gly Gin Leu Trp Gin Ala Lys Trp Trp Thr 530 535 540 Gin Asn Gin Glu Pro Gly Asp Pro Tyr Gly Pro Trp Glu Pro Leu Asn 545 550 555 560 SEQ ID No . 7 : ATGAAACAACAAAAACGGCTTTACGCCCGATTGCTGACGCTGTTATTTGCGCTCATCTTCT TGCTGCCTCATTCTGCAGC AGCGGCGGCAAATCTTAATgctcccggctgccgcgtcgactacgccgtcaccaaccagtgg cccggcggcttcggcgcca acgtcacgatcaccaacctcggcgaccccgtctcgtcgtggaagctcgactggacctacac cgcaggccagcggatccag cagctgtggaacggcaccgcgtcgaccaacggcggccaggtctccgtcaccagcctgccct ggaacggcagcatcccgac cggcggcacggcgtcgttcgggttcaacggctcgtgggccgggtccaacccgacgccggcg tcgttctcgctcaacggca ccacgtgcactggtacagttcctacaactagtcctacacgtGCAAATCTTAATGGGACGCT GATGCAGTATTTTGAATGG TACATGCCCAATGACGGCCAACATTGGAGGCGTTTGCAAAACGACTCGGCATATTTGGCTG AACACGGTATTACTGCCGT CTGGATTCCCCCGGCATATAAGGGAACGAGCCAAGCGGATGTGGGCTACGGTGCTTACGAC CTTTATGATTTAGGGGAGT TTCATCAAAAAGGGACGGTTCGGACAAAGTACGGCACAAAAGGAGAGCTGCAATCTGCGAT CAAAAGTCTTCATTCCCGC GACATTAACGTTTACGGGGATGTGGTCATCAACCACAAAGGCGGCGCTGATGCGACCGAAG ATGTAACCGCGGTTGAAGT CGATCCCGCTGACCGCAACCGCGTAATTTCAGGAGAACACCTAATTAAAGCCTGGACACAT TTTCATTTTCCGGGGCGCG GCAGCACATACAGCGATTTTAAATGGCATTGGTACCATTTTGACGGAACCGATTGGGACGA GTCCCGAAAGCTGAACCGC ATCTATAAGTTTCAAGGAAAGGCTTGGGATTGGGAAGTTTCCAATGAAAACGGCAACTATG ATTATTTGATGTATGCCGA CATCGATTATGACCATCCTGATGTCGCAGCAGAAATTAAGAGATGGGGCACTTGGTATGCC AATGAACTGCAATTGGACG GTTTCCGTCTTGATGCTGTCAAACACATTAAATTTTCTTTTTTGCGGGATTGGGTTAATCA TGTCAGGGAAAAAACGGGG AAGGAAATGTTTACGGTAGCTGAATATTGGCAGAATGACTTGGGCGCGCTGGAAAACTATT TGAACAAAACAAATTTTAA TCATTCAGTGTTTGACGTGCCGCTTCATTATCAGTTCCATGCTGCATCGACACAGGGAGGC GGCTATGATATGAGGAAAT TGCTGAACGGTACGGTCGTTTCCAAGCATCCGTTGAAATCGGTTACATTTGTCGATAACCA TGATACACAGCCGGGGCAA TCGCTTGAGTCGACTGTCCAAACATGGTTTAAGCCGCTTGCTTACGCTTTTATTCTCACAA GGGAATCTGGATACCCTCA GGTTTTCTACGGGGATATGTACGGGACGAAAGGAGACTCCCAGCGCGAAATTCCTGCCTTG AAACACAAAATTGAACCGA TCTTAAAAGCGAGAAAACAGTATGCGTACGGAGCACAGCATGATTATTTCGACCACCATGA CATTGTCGGCTGGACAAGG GAAGGCGACAGCTCGGTTGCAAATTCAGGTTTGGCGGCATTAATAACAGACGGACCCGGTG GGGCAAAGCGAATGTATGT CGGCCGGCAAAACGCCGGTGAGACATGGCATGACATTACCGGAAACCGTTCGGAGCCGGTT GTCATCAATTCGGAAGGCT GGGGAGAGTTTCACGTAAACGGCGGGTCGGTTTCAATTTATGTTCAAAGATAG SEQ ID No . 8 : MKQQKRLYARLLTLLFALIFLLPHSAAAAanlnapgcrvdyavtnqwpggfganvtitnlg dpvsswkldwtytagqriq qlwngtastnggqvsvtslpwngsiptggtasfgfngswagsnptpasfslngttctgtvp ttsptrANLNGTLMQYFE YMPNDGQHWRRLQNDSAYLAEHGITAV IPPAYKGTSQADVGYGAYDLYDLGEFHQKGTVR TKYGTKGELQSAIKSLHSR DINVYGDWINHKGGADATEDVTAVEVDPADRNRVISGEHLIKAWTHFHFPGRGSTYSDFK WHWYHFDGTDWDESRKLNR IYKFQGKAWDWEVSNENGNYDYLMYADIDYDHPDVAAEIKRWGTWYANELQLDGFRLDAVK HIKFSFLRDWVNHVREKTG KEMFTVAEYWQNDLGALENYLNKTNFNHSVFDVPLHYQFHAASTQGGGYDMRKLLNGTWS KHPLKSVTFVDNHDTQPGQ SLESTVQTWFKPLAYAFI TRESGYPQVFYGDMYGTKGDSQREIPALKHKIEPILKARKQY AYGAQHDYFDHHDIVGWTR EGDSSVANSGLAALITDGPGGAKRMYVGRQNAGETWHDITGNRSEPVVINSEGWGEFHVNG GSVSIYVQRZ SEQ ID No . 9 : GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCAC GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA CTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGT GAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGC CTGCAGGTCGACGCATTCCGAATACGAGGCCTGATTAATGATTACATACGCCTCCGGGTAG TAGACCGAGCAGCCGAGCCAGTTCAGCGCCTAAAACGCCTTATACAATTAAGCAGTTAAAG AAGTTAGAATCTACGCTTAAAAAGCTACTTAAAAATCGATCTCGCAGTCCCGATTCGCCTA TCAAAACCAGTTTAAATCAACTGATTAAAGGTGCCGAACGAGCTATAAATGATATAACAAT ATTAAAGCATTAATTAGAGCAATATCAGGCCGCGCACGAAAGGCAACTTAAAAAGCGAAAG CGCTCTACTAAACAGATTACTTTTGAAAAAGGCACATCAGTATTTAAAGCCCGAATCCTTA TTAAGCGCCGAAATCAGGCAGATAAAGCCATACAGGCAGATAGACCTCTACCTATTAAATC GGCTTCTAGGCGCGCTCCATCTAAATGTTCTGGCTGTGGTGTACAGGGGCATAAAATTACG CACTACCCGAATCGATAGAACTACTCATTTTTATATAGAAGTCAGAATTCATAGTGTTTTG ATCATTTTAAATTTTTATATGGCGGGTGGTGGGCAACTCGCTTGCGCGGGCAACTCGCTTA CCGATTACGTTAGGGCTGATATTTACGTGAAAATCGTCAAGGGATGCAAGACCAAAGTAGT AAAACCCCGGAAGTCAACAGCATCCAAGCCCAAGTCCTTCACGGAGAAACCCCAGCGTCCA CATCACGAGCGAAGGACCACCTCTAGGCATCGGACGCACCATCCAATTAGAAGCAGCAAAG CGAAACAGCCCAAGAAAAAGGTCGGCCCGTCGGCCTTTTCTGCAACGCTGATCACGGGCAG CGATCCAACCAACACCCTCCAGAGTGACTAGGGGCGGAAATTTAAAGGGATTAATTTCCAC TCAACCACAAATCACAGTCGTCCCCGGTATTGTCCTGCAGAATGCAATTTAAACTCTTCTG CGAATCGCTTGGATTCCCCGCCCCTAGTCGTAGAGCTTAAAGTATGTCCCTTGTCGATGCG ATGATACACAACATATAAATACTAGCAAGGGATGCCATGCTTGGAGGATAGCAACCGACAA CATCACATCAAGCTCTCCCTTCTCTGAACAATAAACCCCACAGGGGGGATCCACTAGTAAC GGCCGCCAGTGTGCTGGAAAGCGACTTGAAACGCCCCAAATGAAGTCCTCCATCCTCGCCA GCGTCTTCGCCACGGGCGCCGTGGCTCAAAGTGGTCCGTGGCAGCAATGTGGTGGCATCGG ATGGCAAGGATCGACCGACTGTGTGTCGGGCTACCACTGCGTCTACCAGAACGATTGGTAC AGCCAGTGCGTGCCTGGCGCGGCGTCGACAACGCTGCAGACATCGACCACGTCCAGGCCCA CCGCCACCAGCACCGCCCCTCCGTCGTCCACCACCTCGCCTAGCGTGGCCAGTCCTATTCG TCGAGAGGTCTCGCAGGATCTGTTTAACCAGTTCAATCTCTTTGCACAGTATTCTGCAGCC GCATACTGCGGAAAAAACAATGATGCCCCAGCTGGTACAAACATTACGTGCACGGGAAATG CCTGCCCCGAGGTAGAGAAGGCGGATGCAACGTTTCTCTACTCGTTTGAAGACTCTGGAGT GGGCGATGTCACCGGCTTCCTTGCTCTCGACAACACGAACAAATTGATCGTCCTCTCTTTC CGTGGCTCTCGTTCCATAGAGAACTGGATCGGGAATCTTAAGTTCCTCTTGAAAAAAATAA ATGACATTTGCTCCGGCTGCAGGGGACATGACGGCTTCACTTCGTCCTGGAGGTCTGTAGC CGATACGTTAAGGCAGAAGGTGGAGGATGCTGTGAGGGAGCATCCCGACTATCGCGTGGTG TTTACCGGACATAGCTTGGGTGGTGCATTGGCAACTGTTGCCGGAGCAGACCTGCGTGGAA ATGGGTATGATATCGACGTGTTTTCATATGGCGCCCCCCGAGTCGGAAACAGGGCTTTTGC AGAATTCCTGACCGTACAGACCGGCGGAACACTCTACCGCATTACCCACACCAATGATATT GTCCCTAGACTCCCGCCGCGCGAATTCGGTTACAGCCATTCTAGCCCAGAATACTGGATCA AATCTGGAACCCTTGTCCCCGTCACCCGAAACGATATCGTGAAGATAGAAGGCATCGATGC CACCGGCGGCAATAACCGGCCGAACATTCCGGATATCCCTGCGCACCTATGGTACTTCGGG TTAATTGGGACATGTCTTTAGTGGCCGGCGCGGCTGGGTCGACTCTAGCGAGCTCGAGATC TAGAGGGTGACTGACACCTGGCGGTAGACAATCAATCCATTTCGCTATAGTTAAAGGATGG GGATGAGGGCAATTGGTTATATGATCATGTATGTAGTGGGTGTGCATAATAGTAGTGAAAT GGAAGCCAAGTCATGTGATTGTAATCGACCGACGGAATTGAGGATATCCGGAAATACAGAC ACCGTGAAAGCCATGGTCTTTCCTTCGTGTAGAAGACCAGACAGACAGTCCCTGATTTACC CTTGCACAAAGCACTAGAAAATTAGCATTCCATCCTTCTCTGCTTGCTCTGCTGATATCAC TGTCATTCAATGCATAGCCATGAGCTCATCTTAGATCCAAGCACGTAATTCCATAGCCGAG GTCCACAGTGGAGCAGCAACATTCCCCATCATTGCTTTCCCCAGGGGCCTCCCAACGACTA AATCAAGAGTATATCTCTACCGTCCAATAGATCGTCTTCGCTTCAAAATCTTTGACAATTC CAAGAGGGTCCCCATCCATCAAACCCAGTTCAATAATAGCCGAGATGCATGGTGGAGTCAA TTAGGCAGTATTGCTGGAATGTCGGGCCAGTTGGCCCGGGTGGTCATTGGCCGCCTGTGAT GCCATCTGCCACTAAATCCGATCATTGATCCACCGCCCACGAGGCGCGTCTTTGCTTTTTG CGCGGCGTCCAGGTTCAACTCTCTCGCTCTAGATATCGATGAATTCACTGGCCGTCGTTTT ACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCC CCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGC GCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTAT TTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAG CCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCG CTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATC ACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTA TTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATA AATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTT ATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAG TAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG CGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAA GTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCC GCATACACTATTCTCAGAATGACTTGGTTGACGCGTCACCAGTCACAGAAAAGCATCTTAC GGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCG GCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACA TGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAA CGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACT GGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAG TTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCC CGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGA TCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATA TATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTT TTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACC CCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTT GCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACT CTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGT AGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCT AATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCA AGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGC CCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA GGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGT TTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATG GAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCAC ATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAG CTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGA AGAGAG SEQ ID No. 10: GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCAC GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA CTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGT GAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGC CTGCAGGTCGACGCATTCCGAATACGAGGCCTGATTAATGATTACATACGCCTCCGGGTAG TAGACCGAGCAGCCGAGCCAGTTCAGCGCCTAAAACGCCTTATACAATTAAGCAGTTAAAG AAGTTAGAATCTACGCTTAAAAAGCTACTTAAAAATCGATCTCGCAGTCCCGATTCGCCTA TCAAAACCAGTTTAAATCAACTGATTAAAGGTGCCGAACGAGCTATAAATGATATAACAAT ATTAAAGCATTAATTAGAGCAATATCAGGCCGCGCACGAAAGGCAACTTAAAAAGCGAAAG CGCTCTACTAAACAGATTACTTTTGAAAAAGGCACATCAGTATTTAAAGCCCGAATCCTTA TTAAGCGCCGAAATCAGGCAGATAAAGCCATACAGGCAGATAGACCTCTACCTATTAAATC GGCTTCTAGGCGCGCTCCATCTAAATGTTCTGGCTGTGGTGTACAGGGGCATAAAATTACG CACTACCCGAATCGATAGAACTACTCATTTTTATATAGAAGTCAGAATTCATAGTGTTTTG ATCATTTTAAATTTTTATATGGCGGGTGGTGGGCAACTCGCTTGCGCGGGCAACTCGCTTA CCGATTACGTTAGGGCTGATATTTACGTGAAAATCGTCAAGGGATGCAAGACCAAAGTAGT AAAACCCCGGAAGTCAACAGCATCCAAGCCCAAGTCCTTCACGGAGAAACCCCAGCGTCCA CATCACGAGCGAAGGACCACCTCTAGGCATCGGACGCACCATCCAATTAGAAGCAGCAAAG CGAAACAGCCCAAGAAAAAGGTCGGCCCGTCGGCCTTTTCTGCAACGCTGATCACGGGCAG CGATCCAACCAACACCCTCCAGAGTGACTAGGGGCGGAAATTTAAAGGGATTAATTTCCAC TCAACCACAAATCACAGTCGTCCCCGGTATTGTCCTGCAGAATGCAATTTAAACTCTTCTG CGAATCGCTTGGATTCCCCGCCCCTAGTCGTAGAGCTTAAAGTATGTCCCTTGTCGATGCG ATGATACACAACATATAAATACTAGCAAGGGATGCCATGCTTGGAGGATAGCAACCGACAA CATCACATCAAGCTCTCCCTTCTCTGAACAATAAACCCCACAGGGGGGATCCACTAGTAAC GGCCGCCAGTGTGCTGGAAAGCGACTTGAAACGCCCCAAATGAAGTCCTCCATCCTCGCCA GCGTCTTCGCCACGGGCGCCGTGGCTCAAAGTGGTCCGTGGCAGCAATGTGGTGGCATCGG ATGGCAAGGATCGACCGACTGTGTGTCGGGCTACCACTGCGTCTACCAGAACGATTGGTAC AGCCAGTGCGctageCCTccTCGTCGAcctGTCTCGCAGGATCTGTTTAACCAGTTCAATC TCTTTGCACAGTATTCTGCAGCCGCATACTGCGGAAAAAACAATGATGCCCCAGCTGGTAC AAACATTACGTGCACGGGAAATGCCTGCCCCGAGGTAGAGAAGGCGGATGCAACGTTTCTC TACTCGTTTGAAGACTCTGGAGTGGGCGATGTCACCGGCTTCCTTGCTCTCGACAACACGA ACAAATTGATCGTCCTCTCTTTCCGTGGCTCTCGTTCCATAGAGAACTGGATCGGGAATCT TAAGTTCCTCTTGAAAAAAATAAATGACATTTGCTCCGGCTGCAGGGGACATGACGGCTTC ACTTCGTCCTGGAGGTCTGTAGCCGATACGTTAAGGCAGAAGGTGGAGGATGCTGTGAGGG AGCATCCCGACTATCGCGTGGTGTTTACCGGACATAGCTTGGGTGGTGCATTGGCAACTGT TGCCGGAGCAGACCTGCGTGGAAATGGGTATGATATCGACGTGTTTTCATATGGCGCCCCC CGAGTCGGAAACAGGGCTTTTGCAGAATTCCTGACCGTACAGACCGGCGGAACACTCTACC GCATTACCCACACCAATGATATTGTCCCTAGACTCCCGCCGCGCGAATTCGGTTACAGCCA TTCTAGCCCAGAATACTGGATCAAATCTGGAACCCTTGTCCCCGTCACCCGAAACGATATC GTGAAGATAGAAGGCATCGATGCCACCGGCGGCAATAACCGGCCGAACATTCCGGATATCC CTGCGCACCTATGGTACTTCGGGTTAATTGGGACATGTCTTTAGTGGCCGGCGCGGCTGGG TCGACTCTAGCGAGCTCGAGATCTAGAGGGTGACTGACACCTGGCGGTAGACAATCAATCC ATTTCGCTATAGTTAAAGGATGGGGATGAGGGCAATTGGTTATATGATCATGTATGTAGTG GGTGTGCATAATAGTAGTGAAATGGAAGCCAAGTCATGTGATTGTAATCGACCGACGGAAT TGAGGATATCCGGAAATACAGACACCGTGAAAGCCATGGTCTTTCCTTCGTGTAGAAGACC AGACAGACAGTCCCTGATTTACCCTTGCACAAAGCACTAGAAAATTAGCATTCCATCCTTC TCTGCTTGCTCTGCTGATATCACTGTCATTCAATGCATAGCCATGAGCTCATCTTAGATCC AAGCACGTAATTCCATAGCCGAGGTCCACAGTGGAGCAGCAACATTCCCCATCATTGCTTT CCCCAGGGGCCTCCCAACGACTAAATCAAGAGTATATCTCTACCGTCCAATAGATCGTCTT CGCTTCAAAATCTTTGACAATTCCAAGAGGGTCCCCATCCATCAAACCCAGTTCAATAATA GCCGAGATGCATGGTGGAGTCAATTAGGCAGTATTGCTGGAATGTCGGGCCAGTTGGCCCG GGTGGTCATTGGCCGCCTGTGATGCCATCTGCCACTAAATCCGATCATTGATCCACCGCCC ACGAGGCGCGTCTTTGCTTTTTGCGCGGCGTCCAGGTTCAACTCTCTCGCTCTAGATATCG ATGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAAC TTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCAC CGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTT CTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCT CTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACG GGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATG TGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCC TATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCG GGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCG CTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTA TTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGC TCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGT TACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTT TTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGC CGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGACGCGTCA CCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCA TAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGA GCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCG GAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAA CAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGC TGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCAC TGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAAC TATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAA CTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTA AAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTT TTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTT TTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTT TGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGAT ACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCA CCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGT CGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTG AACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATAC CTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATC CGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGC TCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGG CCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAA CCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGC GAGTCAGTGAGCGAGGAAGCGGAAGAGAG SEQ ID No. 11: GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCAC GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA CTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGT GAGCOGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTTGCATGC CTGCAGGTCGACGCATTCCGAATACGAGGCCTGATTAATGATTACATACGCCTCCGGGTAG TAGACCGAGCAGCCGAGCCAGTTCAGCGCCTAAAACGCCTTATACAATTAAGCAGTTAAAG AAGTTAGAATCTACGCTTAAAAAGCTACTTAAAAATCGATCTCGCAGTCCCGATTCGCCTA TCAAAACCAGTTTAAATCAACTGATTAAAGGTGCCGAACGAGCTATAAATGATATAACAAT ATTAAAGCATTAATTAGAGCAATATCAGGCCGCGCACGAAAGGCAACTTAAAAAGCGAAAG CGCTCTACTAAACAGATTACTTTTGAAAAAGGCACATCAGTATTTAAAGCCCGAATCCTTA TTAAGCGCCGAAATCAGGCAGATAAAGCCATACAGGCAGATAGACCTCTACCTATTAAATC GGCTTCTAGGCGCGCTCCATCTAAATGTTCTGGCTGTGGTGTACAGGGGCATAAAATTACG CACTACCCGAATCGATAGAACTACTCATTTTTATATAGAAGTCAGAATTCATAGTGTTTTG ATCATTTTAAATTTTTATATGGCGGGTGGTGGGCAACTCGCTTGCGCGGGCAACTCGCTTA CCGATTACGTTAGGGCTGATATTTACGTGAAAATCGTCAAGGGATGCAAGACCAAAGTAGT AAAACCCCGGAAGTCAACAGCATCCAAGCCCAAGTCCTTCACGGAGAAACCCCAGCGTCCA CATCACGAGCGAAGGACCACCTCTAGGCATCGGACGCACCATCCAATTAGAAGCAGCAAAG CGAAACAGCCCAAGAAAAAGGTCGGCCCGTCGGCCTTTTCTGCAACGCTGATCACGGGCAG CGATCCAACCAACACCCTCCAGAGTGACTAGGGGCGGAAATTTAAAGGGATTAATTTCCAC TCAACCACAAATCACAGTCGTCCCCGGTATTGTCCTGCAGAATGCAATTTAAACTCTTCTG CGAATCGCTTGGATTCCCCGCCCCTAGTCGTAGAGCTTAAAGTATGTCCCTTGTCGATGCG ATGATACACAACATATAAATACTAGCAAGGGATGCCATGCTTGGAGGATAGCAACCGACAA CATCACATCAAGCTCTCCCTTCTCTGAACAATAAACCCCACAOGGGGGATCCACTAGTAAC GGCCGCCAGTGTGCTGGAAAGCGACTTGAAACGCCCCAAATGAAGTCCTCCATCCTCGCCA GCGTCTTCGCCACGGGCGCCGTGGCTCAAAGTGGTCCGTGGCAGCAATGTGGTGGCATCGG ATGGCAAGGATCGACCGACTGTGTGTCGGGCTACCACTGCGTCTACCAGAACGATTGGTAC AGCCAGTGCGCTAGCGTCCAGATCCCCTCCAGCAGCACCAGCTCTCCGGTCAACCAGCCTA CCAGCACCAGCACCACGTCCACCTCCACCACCTCGAGCCCGCCAGTCCAGCCTACGACTCC CAGCGCTAGCCCTCCTCGTCGACCTGTCTCGCAGGATCTGTTTAACCAGTTCAATCTCTTT GCACAGTATTCTGCAGCCGCATACTGCGGAAAAAACAATGATGCCCCAGCTGGTACAAACA TTACGTGCACGGGAAATGCCTGCCCCGAGGTAGAGAAGGCGGATGCAACGTTTCTCTACTC GTTTGAAGACTCTGGAGTGGGCGATGTCACCGGCTTCCTTGCTCTCGACAACACGAACAAA TTGATCGTCCTCTCTTTCCGTGGCTCTCGTTCCATAGAGAACTGGATCGGGAATCTTAAGT TCCTCTTGAAAAAAATAAATGACATTTGCTCCGGCTGCAGGGGACATGACGGCTTCACTTC GTCCTGGAGGTCTGTAGCCGATACGTTAAGGCAGAAGGTGGAGGATGCTGTGAGGGAGCAT CCCGACTATCGCGTGGTGTTTACCGGACATAGCTTGGGTGGTGCATTGGCAACTGTTGCCG GAGCAGACCTGCGTGGAAATGGGTATGATATCGACGTGTTTTCATATGGCGCCCCCCGAGT CGGAAACAGGGCTTTTGCAGAATTCCTGACCGTACAGACCGGCGGAACACTCTACCGCATT ACCCACACCAATGATATTGTCCCTAGACTCCCGCCGCGCGAATTCGGTTACAGCCATTCTA GCCCAGAATACTGGATCAAATCTGGAACCCTTGTCCCCGTCACCCGAAACGATATCGTGAA GATAGAAGGCATCGATGCCACCGGCGGCAATAACCGGCCGAACATTCCGGATATCCCTGCG CACCTATGGTACTTCGGGTTAATTGGGACATGTCTTTAGTGGCCGGCGCGGCTGGGTCGAC TCTAGCGAGCTCGAGATCTAGAGGGTGACTGACACCTGGCGGTAGACAATCAATCCATTTC GCTATAGTTAAAGGATGGGGATGAGGGCAATTGGTTATATGATCATGTATGTAGTGGGTGT GCATAATAGTAGTGAAATGGAAGCCAAGTCATGTGATTGTAATCGACCGACGGAATTGAGG ATATCCGGAAATACAGACACCGTGAAAGCCATGGTCTTTCCTTCGTGTAGAAGACCAGACA GACAGTCCCTGATTTACCCTTGCACAAAGCACTAGAAAATTAGCATTCCATCCTTCTCTGC TTGCTCTGCTGATATCACTGTCATTCAATGCATAGCCATGAGCTCATCTTAGATCCAAGCA CGTAATTCCATAGCCGAGGTCCACAGTGGAGCAGCAACATTCCCCATCATTGCTTTCCCCA GGGGCCTCCCAACGACTAAATCAAGAGTATATCTCTACCGTCCAATAGATCGTCTTCGCTT CAAAATCTTTGACAATTCCAAGAGGGTCCCCATCCATCAAACCCAGTTCAATAATAGCCGA GATGCATGGTGGAGTCAATTAGGCAGTATTGCTGGAATGTCGGGCCAGTTGGCCCGGGTGG TCATTGGCCGCCTGTGATGCCATCTGCCACTAAATCCGATCATTGATCCACCGCCCACGAG GCGCGTCTTTGCTTTTTGCGCGGCGTCCAGGTTCAACTCTCTCGCTCTAGATATCGATGAA TTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAAT CGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATC GCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCT TACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGAT GCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTT GTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCA GAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTT TTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAA ATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCAT GAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAA CATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACC CAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACAT CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCA ATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGC AAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGACGCGTCACCAGT CACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAA CCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCT GAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACG TTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACT GGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTT TATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGG CCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGG ATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTC AGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGG ATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGT TCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCT GCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCG GATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAA ATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCC TACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGT CTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGG GGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACA GCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTA AGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTC AGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTT TGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTA TTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTC AGTGAGCGAGGAAGCGGAAGAGAG

Claims: CLAIMS 1. A process for desizing cellulose-containing fabric or tex¬ tile, wherein said fabric or textile is treated with a modified enzyme (enzyme hybrid) which comprises a catalytically active amino acid sequence of a non-cellulolytic enzyme linked to an amino acid sequence comprising a cellulose-binding domain. 2. A process according to claim 1, wherein said catalytically active amino acid sequence derives from an enzyme selected from the group consisting of amylases and lipases. 3. A process according to claim 2, wherein said amylase is an α-amylase obtainable from a species of Bacillus . 4. A process according to claim 2 or 3, wherein said α-amylase is obtainable from Bacillus licheniformis . 5. A process according to any one of claims 2-4, wherein an amylolytic enzyme hybrid is employed in an amount corresponding to an amylase activity in the range of between 1 and 5000 KNU per litre of desizing liquor. 6. A process according to claim 2, wherein said lipase is obtainable from a species of Humicola , Candida, Pseudomonas or Bacillus . 7. A process according to claim 2 or 6, wherein a lipolytic enzyme hybrid is employed in an amount corresponding to a lipase activity in the range of between 10 and 20000 LU per litre of desizing liquor. 8. A process according to claim 1, wherein said cellulose- binding domain is obtainable from a cellulase, a xylanase, a mannanase, an arabinofuranosidase, an acetylesterase or a chitinase. 9. A process according to claim 1, wherein said enzyme hybrid is obtained by a method comprising growing a transformed host cell containing an expression cassette which comprises a DNA sequence encoding said enzyme hybrid, whereby said enzyme hybrid is expressed. 10. A desizing composition comprising: an enzyme hybrid which comprises a catalytically active amino acid sequence of a non-cellulolytic enzyme linked to an amino acid sequence comprising a cellulose-binding domain; and a wetting agent.

Inventors: BJOERNVAD MADS ESKELUND, RASMUSSEN MICHAEL DOLBERG, VIND JESPER, VON DER OSTEN CLAUS, BJOERNVAD, MADS, ESKELUND, RASMUSSEN, MICHAEL, DOLBERG, VIND, JESPER, VON DER OSTEN, CLAUS
Applicants: BJOERNVAD MADS ESKELUND, NOVONORDISK AS, RASMUSSEN MICHAEL DOLBERG, VIND JESPER, VON DER OSTEN CLAUS, BJOERNVAD, MADS, ESKELUND, NOVO NORDISK A/S, RASMUSSEN, MICHAEL, DOLBERG, VIND, JESPER, VON DER OSTEN, CLAUS
Application year: 1997
Main classification: C12N9
IPC codes: C11D3, C12N9, C12P21, D06L1, D06M16